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Abstract
Although there are many aging-associated retinal diseases, the aging mechanisms
which initiate retinal disease remain elusive. To investigate this problem, a model of
premature aging, the harlequin mouse, was examined for deficits in retinal function,
anatomy and histology, as well as changes in retinal oxidative stress, gene expression and
mitochondrial DNA damage. Retinal function of the harlequin mouse, as assessed by
electroretinography, was compromised in advance of change in retinal anatomy and
histology. Functional deficits occurred in parallel with increased oxidative stress,
assessed by in situ dihydroethidium staining. Furthermore, microarray transcriptome
analysis of harlequin mice identified markers of mitochondrial stress, inflammation, and
retinal remodelling. The random mutation capture assay detected few mitochondrial
deletions, indicating minimal relevance of mitochondrial DNA damage to harlequin
mitochondrial dysfunction and retinal pathology. These data indicate that DNA-damageindependent mitochondrial dysfunction drives a loss of retina function prior to neuron
death in the harlequin model of aging.

Keywords: harlequin, mitochondrial dysfunction, oxidative stress, electroretinography,
aging, retinal degeneration, random mutation capture, mitochondrial deletion, microarray,
inflammation, retinal remodelling.
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Chapter 1 - Introduction
1.1 Growth o f Aging Populations and Increased Neurodegenerative Disease Prevalence
As new medical advances reduce the mortality associated with common illnesses,
and better access to health care increases the longevity of populations in developed
nations, the prevalence of neurodegenerative diseases has increased proportionally.1 The
risk for neurodegenerative disease increases steadily with age, reaching as high as 37.4%
of individuals aged 90 and above.2 Within the next 25 years, the proportion of the
Canadian population over 60 is expected to double to over 9 million people. ’ Based on
the predicted growth in aged populations, the prevalence of Alzheimer’s disease, the most
common form of dementia, is expected to increase by 300% by 2050.4 These increases in
the aged population and in neurodegenerative disease prevalence have the potential to
become a significant detriment to individual quality of life and national health care
spending in the near future.

1.2 High Prevalence and Staggering Costs o f Retinal Degenerative Diseases
Although not all neurodegenerative diseases are fatal, nearly all are a detriment to
the quality of life of the affected individuals. Some of the most pronounced examples of
this are the retinal degenerative diseases, as they can permanently compromise the vision
of individuals affected. The combined prevalence of the three most common retinal
degenerative diseases, age-related macular degeneration (AMD), open-angle glaucoma
and diabetic retinopathy (DR), exceeds 6.73% in the U.S. population over 40 years of
age.3'7 This substantial percentage of affected individuals also results in a significant
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proportion of health care costs for the visually impaired: a value which is estimated at
over 8.6 billion dollars per year in Canada alone.8 Despite this level of spending, the
majority of retinal conditions remains incurable and has no reliable means of prevention.
As the proportion of the population over 60 increases, the proportion of retinal conditions
will increase, reducing the quality of life and further increasing the cost of health care.
For these reasons, retinal diseases are a topic of national concern.

1.3 Mechanisms Initiating Retinal Degeneration Remain Unclear
A common theme in retinal degenerative disease is increased risk with age.9’10
This feature holds true despite the wide array of pathologies displayed by most retinal
degenerations. For example, AMD is primarily known as disease of lipid and protein
aggregation,11 resulting in the formation of drusen in the subretinal space. Drusen
deposits interfere with oxygen transport,12 causing hypoxia and invasion of the
microvasculature into the macula13 (the area of the retina responsible for central vision).
Open-angle glaucoma is characterized by an increase in intraocular pressure,9 resulting in
damage to retinal neuron axons.14 Although the progression of these diseases is well
established, the age-associated molecular events which initiate them are unclear. As a
result, diagnosis of retinal degenerative diseases relies on symptomatic stages and often
requires some form of structural damage to exist. Treatments are similarly limited due to
the late window of effectiveness for current diagnostic tools. Therefore, a crucial
landmark for the advancement of diagnosis and treatment is the elucidation of the basic
mechanisms contributing to retinal aging and the initiation of retinal disease.
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1.4 Anatomical Organization and Physiology o f the Healthy Retina
The retina is composed of two anatomical regions: the neuronal retina and the
retinal pigmented epithelium. The neuronal retina is subdivided into six layers (from
outermost to innermost): outer segment (OS; Fig 1.1), outer nuclear layer (ONL; Fig 1.1),
outer plexiform layer (OPL; Fig 1.1), inner nuclear layer (1NL; Fig 1.1), inner plexiform
layer (1PL; Fig 1.1), and ganglion cell layer (GCL; Fig 1.1). These layers of the retina
are composed of a number of different cell types with a specific organization. Beginning
with the deepest layer, the OS layer contains stacked photoreceptor membranes which
absorb light, converting it into an electrochemical signal. Photoreceptor outer segments
differ in morphology and absorption spectrum depending on the type of photoreceptor.
Rod cells are sensitive to low light levels and cannot distinguish between different light
wavelengths. Cone cells require higher light levels and, in humans, are sensitive to red,
green or blue light wavelengths. The ONL contains the cell bodies of the photoreceptors
which are separated from the OS by the external limiting membrane. The OPL contains
the neurites of bipolar and horizontal neurons, which synapse with the photoreceptors.
The INL contains cell bodies for these bipolar and horizontal cells. Horizontal cells
inhibit photoreceptors, reducing the noise associated with over-stimulation, and feed
forward the bipolar cells through the release of gamma aminobutyric acid (GABA)
neurotransmitter.15 Bipolar cells conduct the electrochemical signal from photoreceptors
to ganglion or amacrine cells. The 1PL contains the amacrine cells and the synapses
between ganglion cells and bipolar or amacrine cells. Amacrine cells are thought to
integrate on- and off-bipolar cell signals.16 The innermost layer of the retina, the GCL,
contains the cell bodies and axons of ganglion cells. This layer conducts the
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Figure 1.1. The anatomical features of the mouse eye as demonstrated using
hematoxylin and eosin staining and conceptual diagrams. (A) Light enters the eye
through the cornea before being refracted by the lens to the area centralis. The iris
regulates how much light enters the eye by either contracting or dilating to restrict or
allow more light exposure. The sclera forms a tough external barrier to protect the inner
components of the eye. (B and C) Light passes through the layers of the neuronal retina
before being absorbed by the photoreceptor outer segments (OS). The outer nuclear layer
(ONL) contains the cell bodies of these photoreceptors. The electrochemical signal is
then passed to the bipolar cells through their neurites in the outer plexiform layer (OPL),
passing it through the bipolar cell bodies in the inner nuclear layer (INL) before reaching
the synapse with amacrine and ganglion cells in the inner plexiform layer (IPL). Ganglion
cell bodies and axons form the ganglion cell layer (GCL), which eventually connects to
the brain through the optic nerve. The retinal pigmented epithelium (RPE) is just below
the OS and supports the neuronal retina.
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electrochemical signal through the optic nerve, which finally connects to the brain.
These cell types o f the neuronal retina are all post-mitotic and incapable of regeneration.
Immediately below the OS of the neuronal retina is the retinal pigmented
epithelium (RPE; Fig 1.1). The neuronal retina has a high metabolic rate and requires
one of the densest vascular networks in the body.17 The RPE serves as an intermediary
between the neuronal retina and vascular choroid. The RPE performs many necessary
tasks to support the neuronal retina, such as shuttling nutrients from the blood supply,18
disposing of waste products,19 removing old or damaged photoreceptor outer segments
which are shed and regenerated constantly,20 and preventing access to unwanted cells or
pathogens through the maintenance of the blood retina barrier.18 In summary, the RPE is
the foundation of the neuronal retina, required for many important supporting functions.
Three types of glial cells are essential to retinal function. The first type,
microglia, is a macrophage-lineage cell which is located in brain and retinal tissues.
Blood-brain and blood-retina barriers prevent the infiltration of pathogens and immune
cells alike; therefore, microglia constitute the innate immunity of these otherwise
macrophage-free tissues. In the event of retinal damage, ATP from the injured neuroglial
cells escapes into the surrounding tissues, causing activation and subsequent migration of
microglia from their normal positions in the GCL, 1PL and OPL to the source of the
ATP.

Activation of microglia results in a number of intracellular changes, including

secretion of matrix metalloproteases,22 microglial replication,23 and altered cell
morphology.24 Once at the region of the injury, microglia mediate the inflammatory
response and phagocytose scattered cellular components, playing an essential role in the
clearance of potentially cytotoxic debris. A second glial cell type, astrocytes, are

supportive glial cells with long thin processes which form a meshwork between neurons
and the blood-retina barrier.27 Functions of astrocytes include the transport of nutrients
from the RPE to individual neurons, the clearance of excess neurotransmitters,26 and the
regulation of the blood brain barrier.27 A third glial cell type of importance to the retina
is the Müller glial cell. Müller glia are massive supportive cells which are thought to
regulate the osmohomeostasis of the adult retina.27 These three glial cell types all play
important and diverse roles in the function of the retina.

1.5 The Phototransduction Process and its Relation to Aging and Light Toxicity
Light entering the retina must first pass through the other five layers before being
absorbed in the OS layer. In rod photoreceptors, the primary photopigment, rhodopsin, is
an 11-cis-retinal chromophore bound to a specific opsin protein.

Absorption of light by

opsin results in the conversion of 11-cis-retinal into all-trans-retinal.26 This isomerization
causes a conformational change in rhodopsin, allowing it to activate the G-protein
transducin.’0 Transducin activates phosphodiesterases, causing a decrease in
photoreceptor concentrations o f cGM P.'1 The decrease of cGMP causes the closing of
cGMP-gated Na* and Ca2+ channels and the hyperpolarization of the photoreceptor/2
Hyperpolarization of the photoreceptor inhibits release of the inhibitory neurotransmitter
glutamate, resulting in a depolarization of downstream bipolar cells.

Eventually, the

various bipolar cell inputs are integrated by amacrine and ganglion cells and are
assembled by the brain into a visual interpretation of the absorbed light. Cone
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photoreceptors have a similar phototransduction process; however, the opsin proteins in
the cone photopsins differ slightly in their absorbance spectra.
The phototransduction process is closely related to retinal aging. Photoreceptors,
particularly rod photoreceptors, are susceptible to loss with age. ” High levels of light
have a similar tendency to cause rod degeneration.34 It has been shown that rearing mice
in dark conditions can preserve rod photoreceptors.37 Both aging and light toxicity also
correspond to increased levels of reactive oxygen species in photoreceptors.36'37 It is
therefore possible that overstimulation o f the phototransduction pathway can have
detrimental effects on cellular physiology relevant to aging.

1.6 In Vivo Assessment o f Retinal Function Using Electroretinography
The physiology of phototransduction can be utilized to quantify the efficiency of
retinal function in response to a light stimulus. This technique, known as
electroretinography (ERG), uses the placement of an electrode on the cornea of an eye to
measure electrical responses of the retina to light pulses. Two primary outputs are
generated from this measurement, an ¿/-wave and a A-wave (Fig 1.2). The o-wave is
related to the negative membrane potential associated with the hyperpolarization of
photoreceptors.

The b-wave is associated with the positive evoked potential related to

the depolarization of bipolar neurons.39 Based on the conditions applied, it is possible to
assay the function of multiple types of photoreceptors. If an individual is dark-adapted
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Figure 1.2. A conceptual representation of electroretinography a-wave and b-wave
outputs. (A) A representation of an electroretinography trace for a healthy individual is
shown. The a-wave is the initial negative component, which is representative of the
hyperpolarization of photoreceptors in response to light. The A-wave is the secondary
positive portion o f the electroretinogram, which corresponds to the depolarization of
bipolar cells. The wave-like spikes above at the apex of the A-wave are known as the
oscillatory potentials and are indicative of amacrine cell function. The x-axis of the
electroretinogram is the time course of the retinal response in ms. The y-axis is the
evoked potential in pV which is detected by the corneal electrode. (B) In an unhealthy
individual, degeneration of the photoreceptor, bipolar, or amacrine cells is reflected by a
reduced amplitude of the corresponding waves. The electroretinogram shown has deficits
in all three markers, indicating a severe, multi-cell pathology of the retina.

Evoked Potential: 200 jiV/division

Evoked Potential: 200 jiV/division

1]

prior to ERG and low levels of light are used, then rod photoreceptors or scotopic vision
are assessed. If high or specifically coloured light is used, then primarily cone
photoreceptors or photopic vision are measured. The ERG a-wave and /»-wave are
versatile tools for the quantification of retinal function in vivo.

1.7 In Vivo Assessment o f Ocular Structure Using Optical Coherence Tomography
Optical coherence tomography (OCT) is an imaging technique used for the
clinical diagnosis of ocular structure abnormalities. The technology itself utilizes the
reflectance of a near-infrared light beam off of the ocular structures under examination.
The reflected beam is detected and compared to a reference beam, allowing the
interference and coherence of the beams to form a negative representation of the
thickness and density of the tissue under examination.40 The continual scanning o f the
retina by the near-infrared beam allows for cross-sectional images of the eye to be
generated and provides an in vivo representation of the internal structure of the eye.

1.8 Oxidative Stress and Aging
Since the first publication proposing free radical attack as a potential cause of
cellular damage and aging,41 the free radical theory of aging has rapidly gained interest in
the scientific community. The current version of this hypothesis, oxidative stress theory,
states that the imbalance of reactive oxygen species (ROS) and anti-oxidant mechanisms
results in a cumulative build-up of oxidative damage to DNA, lipids and protein in post

mitotic cells.42 ROS are oxygen-derived molecules with a highly unstable unpaired
electron in their outer valence shell. The generation of ROS can occur spontaneously
through the reaction of ambient oxygen with reduced metals ions or protein complexes, a
phenomenon which occurs frequently in mitochondria due to high rate of electron
transfer in oxidative phosphorylation (OX-PHOS).43 It has been postulated in many
hypotheses of aging that mitochondria-derived ROS are the damaging force which drives
the aging process. ’
The major sources of ROS production in mitochondria are OX-PHOS complexes
1 and 111.46 These two complexes, along with complex IV form supercomplexes along the
mitochondrial inner membrane.47 The proper assembly of complex I appears to require
supercomplex interaction with complex III.47 Supercomplex formation is thought to
increase OX-PHOS efficiency due to enhanced electron transfer and complex stability.47
Recent evidence has shown that supercomplex dissociation occurs in aging
cardiomyocyte mitochondria,48 potentially explaining the age-dependent decrease in
oxidative capacity46 and the increase in oxidative stress observed in heart mitochondria.
Furthermore, it has been shown that destabilization of these supercomplexes can occur
through the oxidative modification of OX-PHOS complex IV,30 presenting the possibility
of an oxidative stress positive feedback loop. Based on this evidence, it seems probable
that complex and supercomplex assembly are intricately linked with the proper function
of the OX-PHOS machinery and the generation of ROS in aging.
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1.9 Evidence o f Oxidative Stress and Mitochondrial Dysfunction in Aging-Associated
Diseases
The downstream effects of oxidative stress are diverse, ranging from altered gene
expression,M inflammation/1and cell cycle arrest,52 to apoptosis13. It is due to this
diversity of phenotypic responses that oxidative stress could potentially be linked to a
number of age-associated pathologies. Oxidized protein variants have been identified in
neuronal tissues of Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic Lateral
Sclerosis (ALS) and Huntington’s Disease patients.54 Oxidized DNA adducts and
increased ROS production were observed in Leber’s herditary optic neuropathy, a
mitochondrial mutation induced retinopathy.55'56 Increased levels of oxidized
phospholipids have been identified in Age-Related Macular Degeneration (AMD),17
while Glaucoma has been correlated with protein and lipid oxidation products as well as
oxidized DNA bases.18 ln ALS, microglial cells can cause neurodegeneration through the
elevation of extracellular superoxide levels.39 It is therefore possible that the ageassociated disease initiation for a wide range of retinal and neural degenerations is
mediated through oxidative stress.

1.10 Mitochondrial DNA Damage in Retinal Degeneration
A major effect of oxidative stress on DNA is the creation of DNA adducts, the
most common being 8-hydroxy-2-deoxyguanosine (8-OHdG).60 A prominent mechanism
of 8-OHdG formation is the formation of oxygen radicals through Fenton chemistry.
Fenton chemistry involves the reduction of H2 O2 to the extremely damaging hydroxyl
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radical by reduced metal cations such as Fe

and Cu found in high concentration in

mitochondrial membranes.61 Hydroxyl radicals are then prone to attack DNA strands,
causing pro-mutagenic lesions and strand-breakage.62 The main vertebrate mitochondrial
repair mechanism for the 8-OHdG adduct is base excision repair via mitochondrial
Oxidative Damage Endonuclease.

Base excision repair creates single-stranded nicks

and abasic sites which become Double-Stranded Breaks (DSB) if not repaired prior to
DNA replication.64 The creation of DSBs leads to deletions through the Non
Homologous End Joining (NHEJ) repair mechanism/0 NHEJ is the formation of a
duplex between the broken strand and a similar region on another chromosome, thus
giving the broken strand a template for elongation.64 However, due to repetitive or similar
sequences of DNA, the broken strands can mispair to non-homologous regions and cause
DNA deletions.64 In summary, oxidative stress can induce DNA deletions through strand
breakage and the NHEJ repair pathway, presenting a possible link between oxidative
stress and deleterious mutation accumulation with age. As such, this accumulation of
mutations could potentially be an important factor in the initiation of age-associated
disease.42
The mammalian mitochondrial genome is a highly conserved, 16-17 kb, circular
chromosome with 24 non-coding and 13 protein-coding genes.66 Mitochondrial DNA
(mtDNA) is generally free of intronic and intergenic DNA except for a short region
known as the D-Loop (bp 15423-16299).66 Due to the proximity of mitochondrial DNA
to the electron transport chain, the mitochondrial genome is regularly exposed to the
damaging effects of oxidative stress. One hypothesis of aging-associated
neurodegeneration proposes that progressive damage and mutation of mtDNA is a
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causative factor in mitochondrial dysfunction and cell death. The recent discovery of
mitochondrial DNA damage in a model of diabetic retinopathy supports this hypothesis.67
However, contrasting evidence suggests a limited role of mitochondrial DNA damage in
aging pathology. Mitochondrial mutator mice (PolGmut/mut) with an error-prone
mitochondrial polymerase demonstrate the premature aging phenotype that would be
expected from mitochondrial mutation-induced dysfunction.6* However, these mice were
lacking the expected increase in oxidative stress that should accompany normal aging.69
It was also noted that heterozygotes for the polymerase mutation experienced up to 500
times the point mutation load of wild type mice without any phenotypic effect.7"
Although mitochondria have 2-10 mtDNA copies each71 and can tolerate a high degree of
mutational heteroplasniy (up to 70% of mtDNA copies mutated),66 it would appear that
mitochondrial point mutations have little effect on overall phenotype.
Although mitochondrial point mutations have not been correlated with phenotypic
aging, mitochondrial deletion mutations remain a subject of debate. A recent study has
found that aging may be correlated to the copy number of large mtDNA deletions; 72
however, the rarity of the de novo occurrence of these mutations make the likelihood of
achieving mutational homoplasmy in old age remote. Only deletions created early in life,
which were replicated to sufficient copy number, would be likely to reach the threshold
levels for compromised OX-PHOS.72 Although mtDNA mutations may be a good
indicator of oxidative stress, much doubt remains about their potential role in the
initiation of age-associated neurodegeneration.
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1.11 Assessment o f Mitochondrial Deletions Using Random Mutation Capture
The selection and quantification of mitochondrial mutations is a difficult task.
This is in large part due to the high mtDNA copy number and heteroplasmy, combined
with the corresponding difficulty in manipulating the mitochondrial genome to produce
transgenic mutation reporter assays such as the lacl assay in nuclear DNA. As a result,
many existing methods use quantitative PCR (qPCR)-based methods for the elucidation
of mutation frequency.71'74 However, these methods are prone to over-representation of
mutations due to polymerase error and the generation of new mutations from DNA
adducts,75 resulting in a large discrepancy between different methods.75 The random
mutation capture assay avoids this bias by selecting for mutations prior to PCR
amplification using a restriction digest.7'1 Therefore, only sites with a mutated restriction
enzyme recognition site will be left whole after the digest for PCR amplification (Fig
1.3). The restriction enzyme used in random mutation capture is Taqa\, which
recognizes the 5’ TCGA 3’ sequence. This particular enzyme was selected for its
capability to cleave DNA irrespective of the presence of adducts.76 In order to estimate a
mutant frequency, the number of mtDNA copies is simultaneously ascertained via qPCR
of a control region lacking Taqa\ restriction sites. The added specificity of the restriction
enzyme cleavage combined with the sensitivity of qPCR makes random mutation capture
a powerful assay for the quantification of mitochondrial deletions.
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Figure 1.3. A conceptual diagram of the random mutation capture assay for
mitochondrial deletions. Isolated mitochondrial DNA (mtDNA) is digested with the
Taqa\ restriction enzyme to cleave all wild type mutation targets. Mutation targets with
deletion mutations large enough to eliminate all three of the nested Taqa\ restriction sites
(TCGA) can be successfully amplified by PCR. In order to determine the total number of
mitochondrial DNA copies assayed, another region of the mitochondrial genome lacking
Taqa\ restriction sites is simultaneously quantified using a serial dilution of the mtDNA
and quantitative PCR (qPCR). Once the isolated mutations are confirmed by sequencing,
a mutation frequency can be calculated by dividing the number of mutations found by the
product of the number of mtDNA copies (determined by qPCR) and the total number of
mutant-selection PCR reactions.
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1.12 Accumulation o f Oxidized Proteins and Lipids in Retinal Degeneration
Another popular theory for the degeneration of the retina is that the accumulation
of oxidized lipids and proteins interferes with nutrient transport and creates a toxic
environment. The presence of lipofuscin, pigmented deposits of oxidized lipids and
lysosomal debris, in aged and diseased retinas adds support to this hypothesis.

AMD,

one of the most common forms of retinal degeneration, is characterized by the build-up
of extracellular components between the RPE and Bruch’s membrane. These deposits
are thought to disrupt local nutrient absorption, causing hypoxic stress and resulting in
neovascularization of the retina.12 Although evidence for this theory is compelling,
elevation in lipofuscin levels occurs normally without pathological consequence and
extracellular deposits are not present in all aging-associated retinal diseases. Therefore,
accumulation disorders may only comprise a fraction of total retinal degenerative
diseases.

1.13 The Effects o f Altered Metabolism on Neuronal Function
Oxidative phosphorylation deficiency results in a number of changes to cellular
physiology. A reduction in mitochondrial energy production results in impaired calcium
cycling and mitochondrial Ca2+ overload. High intracellular concentrations ofCa‘+ and
the subsequent activation of calpain have been shown to cause the degradation of neuntes
in a caspase-independent manner.78 Furthermore, neurite degeneration can be induced in
mice using an OX-PHOS uncoupling agent.781 Neurite loss in the context of
mitochondrial disease has also been demonstrated in the ganglion cells of a rat model of
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Leber’s hereditary optic neuropathy.

As such, a reduction in mitochondrial function

can have a direct impact on retinal morphology and function in certain neuronal cell
types.
In the absence of sufficient oxidative phosphorylation, cells must find alternative
sources of energy. The major source of anaerobic energy production is glycolysis.
Glycolysis is a biochemical process which converts glucose to pyruvate in a 1:2 ratio,
while also generating two ATP molecules and reducing two NAD+ molecules to NADH.
However, high levels of glycolysis have been linked to increased oxidative stress81 and
the formation of advanced glycation end-products (AGE).

Although AGEs can be

spontaneously formed from the Maillard reaction of glucose with amino acids, glycolysis
provides aldehydes which are much more reactive.

Once formed, AGEs can be

detected by the receptor of advanced glycation end-products (RAGE). Activation of
RAGE by AGEs can contribute to an inflammatory response.8' This AGE-RAGE
inflammatory initiation has negative effects on retinal function as demonstrated by its
role in proliferative diabetic retinopathy and proliferative vitreoretinopathy.

In

summary, altered metabolic functions can have both direct and indirect impacts on
neuronal function.

1.14 Reactive Gliosis and Microgliosis
The initiation of an inflammatory response can have a number of positive and
negative consequences in the central nervous system. The activation of astrocytes in
response to neuronal damage has been shown to upregulate a number of extracellular and
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cytoskeletal components such as fibronectin, laminin, glial fibrillary acidic protein
(GFAP), and vimentin. The first two of these components are thought to be involved
with endothelial cell interactions in the maintenance of the blood-brain barrier.
However, GFAP and vimentin may comprise structural components which form a barrier
to the regeneration of damaged neurites known as a glial scar.89 Interestingly, the
activation o f microglia also has varied results. Microgliosis has been shown to play a
role in the regeneration of damaged neurites of Rhesus monkeys following traumatic
brain injury*7 and aid in the synaptic plasticity of motoneurons.88 Microglial cells also
undergo phagocytosis of apoptotic cells and prevent inflammatory responses under
normal conditions.89 In contrast, during pro-inflammatory conditions, microglia can
increase oxidative stress,90 and release cytotoxic molecules responsible for
neurodegeneration.91 Despite some positive effects, the activation of glial cells and
inflammation may represent an important part of aging-associated retinal disease.

1.15 The Mouse as a Model Organism fo r Retinal Degeneration Research
The use of model organisms allows for research on the fundamental principles of
diseases which could not be ethically achieved in human subjects. Mice are one of the
most commonly used models of human diseases due to their small size, large litters, short
generation time and similarities in genetic and physiological composition.92 However,
substantial differences do exist between their visual systems. As nocturnal animals, mice
possess vision much more attuned to low light levels. Most of these differences are
accounted for by an increased proportion of rods relative to cones.9’ Mice also lack

cones that are sensitive to the red light,9’ a feature which can be exploited to conduct
experiments which require dark conditions while still being able to observe the mice.
Another key difference is the lack of a macula in mice. The human macula is a ring
shaped protrusion of the retina with a high density of photoreceptors responsible for
central vision. In mice it is replaced by a general increase of photoreceptors in the central
area of the retina.91 Despite these small differences, the basic functional and structural
organization of the mouse retina is largely similar to its human counterpart," making
mouse models a logical choice for the exploration of retinal disease mechanisms.

1.16 The harlequin Mouse Model o f Mitochondrial Dysfunction and Age-Associated
Neurodegeneration
The harlequin (hq) disease mouse (XhqX hq or XhqY) is a model of mitochondrial
dysfunction and oxidative stress resulting in a premature aging phenotype. The hq mouse
displays many of the common aging phenotypic markers, such as decreased fat stores,99
irregular patchy hair growth, an ataxic lateral tremor 97 and progressive retinal and
cerebellar granule neuron degeneration.98 These effects result from a proviral insertion
into an intron 1 regulatory region of the Apoptosis-Inducing Factor (Aif) gene, causing a
global downregulation of the AIF protein.

This downregulation results in mitochondrial

complex 1 deficiency99 and increased oxidative stress,98 resulting in an accelerated-aging
phenotype.

23
1.17 A Review o f Apoptosis-Inducing Factor Function
Th e A if gene is located in the q25-26 region of the human X-chromosome.'00 This
gene codes for a 67 kDa flavoprotein, which is processed to 57 kDa upon transport to the
mitochondrion. Processing enables its conditional apoptosis-inducing capability."10
Upon the opening of the mitochondrial permeability transition pore, AIF translocates to
the nucleus and aids in the condensation of chromatin and the fragmentation of DNA
during apoptosis.100 101 However, this apoptogenic function of AIF only encompasses
one of its multiple functions. Analysis o f the structure of AIF revealed significant
homology to bacterial oxidoreductases,'00 indicating a potential role in mitochondrial
electron transfer. Examination of the AIF-deficient hq mouse revealed increased
oxidative stress across multiple tissues, leading to the hypothesis that AIF may act as a
mitochondrial free radical scavenger.98 Flowever, biochemical analyses of hq brain
mitochondria revealed that there was no increase in mitochondrial generation of ROS
despite AIF deficiency.102 Further analyses of hq mitochondria revealed a significant
decline in OX-PHOS complex I function, indicating a potential role for AIF in the
assembly and/or maintenance of the OX-PHOS I—111 supercomplex.96 99102 Mouse
knock-out models of the A if gene are embryonic-lethal at embryonic day 9, presumably
due to reduced OX-PHOS complex I activity.10' In summary, AIF has diverse and
important roles in cellular function, particularly those relating to OX-PHOS complex
assembly and mitochondrial function.
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1.18 The harlequin Timeline o f Neurodegeneration
Previous characterizations of the hq disease mouse have documented many of the
key landmarks in neurodegenerative onset and progression. The onset of retinal
functional deficits occurs between 5 and 8 weeks of age.98 104 However, histological
evidence of retinal degeneration is not present until a thinning of the outer nuclear layer
at 4 months of age.104 Thinning of the inner nuclear layer also occurred, but not until 8
months of age. The onset of retinal function deficits prior to histological changes
indicates altered physiology of the hq retina, possibly as part of the initiation of retinal
disease. The progression of retinal decline is quite rapid, with severe vision deficits
occurring by 10 months of age.98’104 The cerebellum follows a pattern of
neurodegeneration similar to that of the retina. The onset of cerebellar granule neuron
loss is at 4 months of age,

similar to the degeneration of the retinal granule neurons.

However, a detailed examination of hq cerebellum revealed the degeneration of neurites
at 2 months of age."15 This neurite loss correlated with astrogliosis and microglial
activation.105 Progressive increases in mitochondrial swelling and degeneration were also
observed in the affected cerebellar granule neurons.I(b The loss of neurites in the hq
cerebellum prior to neuron death may represent a potential mechanism for the reduced
function prior to neuron death in the retina.
Much less is known about the heterozygote for the A if proviral insertion, the hq
carrier (hq carrier). Initial characterizations did not reveal any major histological
differences from wild type;98 however, preliminary work has indicated that minor deficits
of retinal function are present early in the hq carrier lifespan. The hq carrier may
therefore represent an intermediate between wild type and hq disease mice.
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1.19 Central Hypothesis
I hypothesize that the AIF-deficiency-induced mitochondrial dysfunction of the
hq mouse results in retinal function deficits prior to anatomical and histological thinning
of the retina. AIF downregulation results in OX-PHOS complex 1 deficiency,
compromising mitochondrial ATP production. Poor mitochondrial function can either
directly induce neurite degeneration through calcium release and calpain-related
pathways, or indirectly via increased glycolysis resulting in an inflammatory response
and synapse disruption. In either case, retinal function is compromised prior to neuron
apoptosis.

1.20 Experimental Aims and Design
The first experimental aim is to determine that retinal physiology is compromised
prior to anatomical and histological thinning. This would establish that gradual
intracellular changes and not massive apoptogenic insults are driving the hq retinal
degeneration. Due to the rapid onset and progression of neurodegeneration in the
homozygote and hemizygote for the hq mutation, structure-function discordance could be
better observed in a more gradual model such as the heterozygote for the hq insertion: the
hq carrier. Retinal function will be assessed using ERG, while thickness of the retinal
layers and the retina proper will be assessed by post-mortem histology and in vivo OCT.
Histological examination will focus on nuclei counts in the layers most affected in the hq
disease mouse: the outer and inner nuclear layers. All phenotyping assays will be
performed on hq carrier and wild type mice at 3, 11, and 15 months of age, corresponding
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to early, middle and middle-late adulthood in the mouse lifespan. It is predicted that with
the more gradual rate of neurodegeneration in the hq carrier, the difference between
functional and structural onset will become more pronounced. In order to validate that
retinal function deficits in hq models are not congenital, ERG will also be performed for
7-week old hq disease mice. Levels of ROS will also be assessed at 11 months of age,
prior to onset of neuron loss, to determine whether oxidative stress is a primary or a
secondary factor in the neurodegenerative mechanism.
The second experimental aim is to determine whether gene expression within the
hq disease retina is altered. This will be instrumental in determining if compensatory
metabolic pathways have been invoked and if markers of inflammation are present. Gene
expression assays will be performed for hq disease mice due to the well characterized
onsets of functional and structural degenerations. Two ages will be examined using gene
expression arrays for both hq disease and wild type mice: a young (5 week) age group
prior to retinal degeneration onset, and an older age group (4 month) which corresponds
to the onset of neuron loss. It is predicted that samples from 5-week-old mice will show
few differences between genotypes, while samples from 4-month-old mice will have a
number of differentially-expressed genes related to mitochondrial dysfunction, metabolic
alteration and inflammation. An additional gene expression study will be conducted
using 4-month-old cerebellum to determine whether disease mechanisms are similar
between retinal and cerebellar granule neurons. It is predicted that the neurodegenerative
pathways will be similar between the two tissue types.
The third experimental aim is to examine the alternate hypothesis of
mitochondrial mutagenesis as a potential initiator of neurodegeneration. Due to the high
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tolerance threshold of mitochondrial mutations, mutations which affect cellular function
are likely to occur early on in development and reach high degree of clonality from
mtDNA replication. As a result of this limitation, increased mtDNA mutations would
have to be present in the pre-disease state in order to play a role in disease initiation.
Therefore, the frequency of mitochondrial deletions will be assessed in the pre-disease
state of the hq disease mouse using the random mutation capture assay. Due to technical
limitations of the mitochondrial random mutation capture assay, the mouse retina is too
small to provide enough mtDNA for accurate mutation quantification. Therefore,
cerebellar mtDNA will be used to assess mitochondrial deletions in the pre-disease state
(1.5 months). It is predicted that the frequency of mitochondrial deletions will not be
different between hq disease and wild type mice.
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CHAPTER 2: Materials and Methods
2.1 Animal Care and Housing
All experimental protocols were approved by The Canadian Council on Animal
Care prior to the experimental start date (Appendix A). The mice were fed a standard
diet [PMI Foods, St. Louis, MO] and water ad libitum. Housing conditions included a
light/dark cycle of 14/10 hours, and a consistent temperature of 21 ± 1°C with relative
humidity of 44-66%.

2.2 Experimental Design fo r Mouse Retinal Pheno typing
Female mice heterozygous for the hq mutation {hq carrier) (B6CBACaAwJ/APcdc8,",/J) [Jackson Laboratories, Bar Harbour, ME] and age-matched wild type controls
were selected in a cohort study of mice 3, 11, and 15 months of age. Mouse A if
genotypes were confirmed using a tri-primer PCR assay as described previously.98
Cohorts of six hq carrier and six wild type mice were selected for each age group for in
vivo assays of retinal function and structure. The right eyes of three hq carrier and three
wild type were selected for post-mortem retinal cell counts at all three ages. All of the
left eyes from the 11-month-old cohort (n=6) were examined for elevated superoxide
anion levels. Five 7-week-old hq disease mice and five age-matched wild type mice were
also selected for electroretinography testing of retinal function.
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2.3 Dark Adaptation and Anaesthesia Preceding In Vivo Testing
Body mass was determined prior to in vivo testing in each cohort and was used to
determine appropriate dose of anaesthesia. Animals were dark adapted for a minimum of
3 hours prior to in vivo testing. Animals were anaesthetized through intraperitoneal
injection of 100 mg/kg ketamine hydrochloride [Bioniche Animal Health Canada,
Belleville, ON] and 5 mg/kg xylazine hydrochloride [Bayer AG, Leverkusen, Germany]
drug mixture. To improve survival rate of the animals under anaesthesia, subcutaneous
0.01 mg/kg atropine [Ayerst Veterinary Laboratories, Guelph, ON] was administered to
reduce the risk of bradycardia and heart failure as a result of ketamine and xylazine
administration. Similarly, 1 mg/kg of intramuscularly delivered atipamezole [Orion
Pharma, Espoo, Finland] was used to reverse the effects of anaesthesia upon completion
of in vivo testing. All anaesthesia and in vivo testing was performed in a dark room with
red safety lights.

2.4 Eleclroretinography (ERG) Assessment o f Retinal Function In Vivo
Mouse pupils were dilated using drops of Diophenyl-T*’ [Sandoz Canada Inc.,
Boucherville, QC] on the corneal surface for approximately 10 min. Drops of Alcaine®
solution [Alcon Canada Inc., Mississauga, ON] were also topically applied to the eyes to
prevent discomfort due to contact with the ERG electrodes. Gold loop electrodes [Grass
Technologies, West Warwick, RI] were placed securely on the cornea and a small
amount of Tear-Gel “ [Novartis Pharmaceuticals Canada Inc., Mississauga, ON] was
applied to keep the eyes hydrated. A gold reference electrode was placed in the mouth of
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the animal, and a grounding wire was inserted subcutaneously into the tail of the animal.
Electrical responses of the retina were elicited using light stimulus from Colordome
Stimulator [Diagnosys, Lowell, MA], Electroretinography mimicked scotopic (primarily
rod photoreceptors) conditions due to the level of dark adaptation. Amplitudes of a- and
b-waves were analyzed at a light intensity of 10 cd*s/m.2 Four replicates were conducted
at this light intensity and their average was used in subsequent data analysis.

2.5 Optical Coherence Tomography (OCT) Assessment o f Retinal Structure In Vivo
Optical Coherence Tomography (OCT) was performed using a Visante™
Instrument [Carl Zeiss Canada Ltd, Toronto, ON]. The OCT instrument was adapted for
mice through the use of a mechanical platform which could be used to steady and orient
the mouse eye. The high resolution scan was centered at the vertex of the mouse eye
prior to image capture. Retinal thickness measures were conducted using the digital
calliper function of the Visante™ software [Carl Zeiss Canada Ltd]. Specific
measurements incorporated both neuronal and retinal pigmented epithelial layers.
Anterior portions of the eyes were examined for any obstructions which could prevent
light passage, with specific focus on opacity of the lens and cornea.

2.6 Tissue Harvest fo r Retinal Phenotyping
Mice were euthanized via CO2 inhalation according to Animal Care and
Veterinary Services (ACVS) standard operating procedure (SOP) 320-02. Left eyes were
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immediately harvested, embedded in optimal cutting temperature media [Somagen
Diagnostics, Edmonton, Alberta], flash frozen on liquid nitrogen and cryopreserved at 80°C. Right eyes used for retinal cell counts were harvested and fixed in Fekete solution
(3.5% formaldehyde, 60% ethanol, 4.3% glacial acetic acid, 0.9% methanol). After
fixation for a minimum 48 hours, eyes were processed using a Leica ASP300 [Leica
Microsystems, Houston, TX] which performed serial I hour ethanol dehydrations with
increasing concentration from 70-100%, as well as three subsequent 1 hour xylene
clearing treatments. Finally, the eyes were subjected to three 1 hour treatments of molten
paraffin wax. These automated steps took 12-16 hours and were performed overnight.

2.7 Hematoxylin and Eosin Retinal Cell Counts and Histological Examination
The paraffin-embedded right eyes were sectioned to a thickness of 10 pm. For
each animal, two C-cut sections (sagittal sections through both the pupil and optic nerve)
were selected for hematoxylin and eosin staining. Digital images were taken at five
different locations (two peripheral retina, three central retina) at 200X magnification
using the Arcturus Veritas microdissection system [Molecular Devices, Sunnyvale, CA].
Peripheral images were taken 300 pm from the ora serrata, while images of the central
retina were captured adjacent to the optic disc and 300 pm to each side the optic disc.
Cell counts were determined at three random locations per image for both the Inner
Nuclear Fayer (INF) and the Outer Nuclear Fayer (ONE). Images were analyzed
according to the region of the retina. All sections and images were examined for
structural abnormalities such as, neovascularization, retinal pigmented epithelium
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disruption, neutrophil invasion, and structural disruption of the retina. Measurements
were performed by two separate scorers blinded to sample identifiers.

2.8 Dihydroethidium (DHE) Staining fo r Semi-Quantitative Determination o f ROS Levels
Cryopreserved left eyes were cryosectioned to a 10 pm thickness using a Leica
CM350 Cryostat [Leica Microsystems], C-cut sections were stored at -20°C until
stained. Cryosectioned left eyes were treated with 50 pL of 5 pM dihydroethidium
(DHE) [Sigma-Aldrich Canada Inc., Oakville, ON] in dimethyl-sulphoxide (DMSO)
[BDH Inc. Toronto, ON] and incubated in a humidified chamber at 37°C for 30 min as
previously described.100 DMSO-treated cryosections served as controls for levels of
autofluorescence in the samples. Specificity of superoxide anion detection was assessed
using a Bovine Superoxide Dismutase (SOD) [Sigma-Aldrich Canada Inc., Oakville, ON]
pre-treatment (10 min with 30 pL of 1000U/mL). Levels of superoxide anions were
quantified using an Arcturus Veritas“ Microdissection System [Molecular Devices] and
the green fluorescence filter capable detecting the DHE emission wavelength of 590 nm.
The fluorescence lamp gain levels were standardized to 3 for all images and analyses.
Images were captured at 200X magnification at three locations, two at the peripheral
retina and one at the central retina, across three tissue sections for each DHE treatment
and control. Intensity of fluorescence was determined at four non-overlapping regions
per image for the ganglion cell layer (GCL), the inner nuclear layer (1NL) and the outer
nuclear layer (ONL). Fluorescence quantitation was performed using ImageJ analysis
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software [National Institute of Health, Bethesda, MD], Analysis was performed
separately by two scorers blinded to animal cohort and identifiers.

2.9 Tissue Harvest fo r Gene Expression Assays
Five-week and four-month-old hq disease and wild type males (n=3) were
euthanized via intraperitoneal injection of 110 mg/kg sodium pentobarbital according to
ACVS SOP 320-02. Right eyes were enucleated and microdissected to remove the whole
retina. Extracted retinas were flash frozen in liquid nitrogen and stored in a -80°C
freezer. Cerebella were also removed and flash frozen in liquid nitrogen. All tools
involved in the microdissection process were baked at 200°C for a minimum of 4 hours,
or were treated with RNaseZAP“ [Sigma-Aldrich, Oakville, Canada] to prevent RNase
contamination.

2.10 RNA Extraction and Purification
Retinal samples were homogenized using a sand homogenization procedure as
described previously.107 Cerebellar samples were added to I mL of Qiazol®lysis reagent
and were homogenized by 20 strokes from a glass type-A pestle in a 7 mL Dounce
homogenizer [Wheaton Science Products, Millville, NJ]. After homogenization, samples
were processed according to standard protocol outlined for RNeasy Mini Spin Columns
[Qiagen Canada Inc., Montreal, QC], This process involved binding RNA to a
membrane within the column, followed by a number of wash steps using buffers RW1B
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and RPE k. After elution from the RNeasy columns, 0.25 volumes of 3M sodium acetate
and 4 volumes of 100% ethanol were added, and the samples were left overnight at
-20°C. Samples were then centrifuged at 4°C and 12000xg for 30 min. The supernatant
was removed carefully and the pellet was washed twice with 80% ethanol and
centrifuged at 4°C and I2000xg for 30 min. The supernatant was removed and the pellet
was air dried and resuspended in RNase-free water. RNA quality was then assessed
using an Agilent 2100 Bioanalyzer [Agilent Technologies Inc., Palo Alto, CA],

2.11 cDNA Synthesis and Hybridization
Synthesis of single-stranded complimentary DNA (cDNA) was performed using
2.0 pg of RNA as described in the product manual of the Ambion WT Expression Kit for
Affymetrix GeneChip Whole Transcript WT Expression Arrays [Applied Biosystems,
Carlsbad, CA]. First-cycle cDNA was transcribed in vitro to cRNA to amplify the total
RNA. Second-cycle cDNA synthesis yielded the minimum 5.5 pg of cDNA which was
subsequently end labeled and hybridized for 16 hours at 45°C to Mouse Gene 1.0 ST
arrays [Affymetrix, Santa Clara, CA], All liquid handling steps were performed by a
GeneChip Fluidics Station 450 and GeneChips were scanned with the GeneChip Scanner
3000 [Affymetrix, Santa Clara, CA] using Command Console v l.l. All GeneChips were
processed at the London Regional Genomics Centre [Robarts Research Institute, London,
ON]
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2.12 Microarray Data Integration and Pathway Analysis
The probe data obtained from the scanning of the Genechips (.CEL tiles) were
analyzed using Partek Genomics Suite v6.5 [Partek Inc., St. Louis, MO], Probe data
were processed and normalized using Robust Multichip Average (RMA) protocols.
Thresholds for differentially-expressed genes were set at a minimum of 2-fold changes in
expression and a maximum p-value of 0.05. KEGG pathway analysis was performed
using the Onto-Tools Suite [Intelligent Systems and Bioinformatics Laboratory, Wayne
State University, Detroit, MI]. Due to the specific nature of retinal markers, geneontology databases did not contain proper categories for the characterization of retinal
degeneration markers. Therefore, the annotation and grouping of differentially-expressed
genes was also performed manually to clarify results from pathway analysis. Annotation
was based on Pubmed [National Institute of Health, Bethesda, MD] literature surveys
using the gene name in combination with the keywords “mitochondria”, “retina”,
“neuron”, “aging”, and “inflammation”.

2.13 Taqman qPCR Confirmation o f Candidate Genes from Microarray Data
O f the differentially-expressed genes, 14 were chosen from pathways relevant to
retinal degeneration in order to confirm data obtained from microarrays. All Taqtnan “
qPCR probes [Applied Biosystems] for the genes of interest were selected to span the
junctions between exons to avoid the possibility of false amplification from genomic
DNA contamination. RNA from original retinal samples used on the microarrays was
first diluted to a concentration of approximately 100 ng/pL, then 9 pL of this RNA was
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added to I pL reverse transcriptase and 10 pL of reverse transcription buffer from the
High-Capacity RNA to cDNA kit“ [Applied Biosystems]. Once converted to cDNA,
Taqman“ qPCR was performed according to the standard protocol for all 4-month retinal
samples and all genes of interest in a single block design (all biological replicates assayed
in parallel). Each gene of interest was assayed in triplicate for each retinal sample and in
duplicate for No-Template Controls (NTC) per qPCR run (Appendix B: Fig B.l). A total
of two qPCR runs were performed using the ABI 7900 HT Fast Real-Time PCR system
[Applied Biosystems]. Expression of genes of interest was normalized to the
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene, a frequently used reference
gene due to its strong and consistent expression.108' 109 Fold-changes were determined
using the AACt relative quantification method.

2.14 Mitochondrial Isolation from the Cerebellum
Protocols for the isolation of mitochondria were adapted from previously
published methods.70 Approximately 50 mg of mouse cerebellum were added to a 7 mL
Dounce homogenizer with 600 pL of homogenization buffer (0.075 M sucrose, 0.225 M
sorbitol, 1 mM EGTA, 0.1% fatty acid free bovine serum albumin (BSA), 10 mM TrisHCI, pH 7.4) and homogenized thoroughly by 20 firm strokes with a type-A glass pestle.
Homogenates were then centrifuged for 10 min at lOOOxg and 4°C to pellet cell debris
and nuclei. The supernatant containing the mitochondrial fraction was decanted and
centrifuged for 15 min at 12000xg and 4°C to form a mitochondrial pellet. After washing
the pellet with cold homogenization buffer and repeating the previous centrifugation step,
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the pellet was resuspended in 650 pL of lysis buffer (10 mM Tris-HCI pH 7.4, 0.15 M
NaCl, 0.05 M EDTA).

2.15 mtDNA Extraction
The protocol for mtDNA extraction was adapted from the standard phenol
chloroform extraction as described previously.76 Steps were carried out using an initial
mitochondrial preparation of 650 pL. After phenol-chloroform extraction, samples were
stored at -80°C for 15 min to precipitate DNA and subsequently centrifuged for 30 min at
12000xg and 4°C. The DNA pellet formed was then rinsed with 70% ethanol,
centrifuged for 5 min at 12000xg, and air-dried to remove ethanol. DNA was dissolved
in 10 mM Tris-HCI.

2.16 mtDNA Quality Control Assessments
In order to assess nuclear DNA contamination, a PCR with the primers specific to
the nuclear-encoded A i f m l gene (Appendix B: Table B.l) was performed using mtDNA
samples as well as positive control samples of conventionally extracted DNA. Also, to
ensure sufficient quantity of mtDNA for subsequent protocols, the amount of DNA was
determined spectrophotometrically using aNanoVue Plus Spectrophotometer [GE
Canada, Mississauga, ON].
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2.17 Taqal Digestion o f mtDNA
Taqa\ digestion was performed in 100 pL reactions containing 100 U of Taqa\
[NEB Canada, Pickering, ON] in a digestion buffer (100 mM NaCl, 10 mM Tris-HCI,
1% BSA, 10 mM MgCh) as described previously.76 DNA concentration was
standardized to approximately 1 pg per reaction. To ensure complete digestion, fresh
Taqa] enzyme was added every hour for 10 hours. Reactions were also thoroughly
mixed immediately after enzyme addition. Digested mtDNA samples stored for extended
periods of time were mixed with EDTA to a final concentration of 10 mM and kept at 20°C.

2.18 Real-time Quantitative PCR and Quantification o f Deletion Mutations
Mitochondrial copy number was determined using a Rotorgene 3000 real-time
PCR instrument [Corbett Research Ltd., Sydney, Australia] and a standard curve based
on a 10-fold dilution series. This standard curve was generated for each run of random
mutation capture using primers specific to a region of the mitochondrial genome lacking
TaqaA restriction sites (Appendix B: Table B.l). PCR amplification was carried out in 20
pL reactions comprised of 10 pL 2X SYBR Brilliant Green Master Mix containing dUTP
[Stratagene, La Jolla, CA], 0.2 pL uracil DNA glycosylase (UDG) [NEB Canada], 1.6 pL
of 10 pM forward and reverse primers, 4.6 pL of Milli-Q [Millipore Canada Ltd.,
Etobicoke, ON] water, and 2 pL of mtDNA. Mutation selection was performed with
identical reaction proportions, but with a set of primers flanking three Taqa\ restriction
sites (Table 1). UDG was added to each reaction to prevent template crossover
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contamination, as any amplicons formed from a previous PCR would contain dUTP and
would be cleaved during an initial 37°C incubation. An initial melt of 95°C to activate
hot-start polymerase enzyme had the additional function of inactivating UDG prior to
PCR amplification. Specific PCR conditions for random mutation capture were
performed as described previously.76

2.19 Deletion Mutant Verification
In order to confirm mutant status from positive real-time PCR results, a number of
quality control assessments were performed. High resolution melt analysis was
performed on the Rotorgene 3000 [Corbett Research Ltd], indicating the temperature
range over which amplicons melted. Low melting temperature peaks and wide melting
ranges are both indicative of the short, heterogeneous nature of primer dimers (Appendix
B: Fig B.2). Bi-modal melt curves are usually indicative of large amplicons with regional
differences in GC content, causing multi-stage melting (Appendix B: Fig B.2).
Amplicons displaying these characteristics were removed from further analysis. To
confirm the presence of a mutant in reactions passing these melt curve criteria, suspected
mutants were re-amplified, purified using the QiaQuick PCR Purification Kit [Qiagen],
and sequenced [Robarts Research Institute],
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2.20 Random Mutation Capture Sensitivity Assay
In order to test whether the random mutation capture experimental design was
capable o f detecting rare mutations in a high background of wild type mitochondrial
DNA (mtDNA), a known deletion mutant was added to a sample of extracted mtDNA.
The copy number of the known mutant was first estimated through qPCR of a dilution
series and the construction of a standard curve. An aliquot of the known mutant was then
diluted to an approximate copy number of 50 and added to a low concentration of
mtDNA and a high concentration of mtDNA (approximately 4-fold more mtDNA than in
the low concentration). The mutant-spiked low and high concentration mtDNA samples
were digested with Taqa\ and screened for deletions using the random mutation capture
assay.

2.21 Statistical Analysis fo r Retinal Phenotyping
All age-specific comparisons of genotypic differences were performed by One
Way ANOVA. Genotype comparisons across multiple ages or multiple parameters were
performed using Multi-Way ANOVAs. Left eye versus right eye comparisons, as well as
inter-scorer comparisons for neuron counts and DHE fluorescence quantification, were
compared by Repeated Measures ANOVA. All data were analyzed using SPSSK)
(Statistical Package for Social Sciences) version 16.0 [IBM Corporation, Somers, NY],
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2.22 Statistical Analysis fo r Gene Expression Studies
Statistical comparisons of microarray probe data were performed using
MANOVA on the Partek Genomics Suite“ v6.5 platform [Partek Inc.]. Statistical
significance for Taqman® qPCR of candidate genes was determined by Repeated
Measures ANOVA. A Pearson’s Correlation Test was also used to compare microarray
and qPCR-derived fold change values. Both the Repeated Measures ANOVA and the
Pearson’s Correlation Test were performed using SPSS [IBM Corporation],
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CHAPTER 3: Results
3.1 A i f genotyping PCR identifies hq carrier, hq disease and wild type mice
The genotypes of each mouse used in this study were confirmed using tri-primer
PCR. PCR using this method results in the formation of a 537 bp amplicon in the
presence o f the wild type ylz/gene and a 725 bp amplicon in the presence of the A if
proviral insertion (Fig 3.1). Both amplicons are produced from heterozygotes for the hq
insertion, hq carriers. A total of 18 hq carrier mice, 17 hq disease, and 35 wild type were
distinguished by this method.

3.2 Electrorelinography (ERG) shows deficits in the retinal function ofhq carrier mice
Analysis of the ERG cr-wave amplitude, the measure of photoreceptor
electrochemical response, revealed a modest, but non-statistically significant weakening
of the a-wave amplitude in 3 and 11 month-old hq carrier mice (Fig 3.2). At 15 months
of age, ¿/-wave amplitude of hq carrier mice deteriorated by 39% in comparison to wild
type mice (p<0.001; Fig 3.2). At 3 months of age, examination of the h-wave amplitude,
a measure of the retinal electrochemical response through the bipolar cells, revealed a
21% decrease in hq carrier mouse h-wave amplitude when compared to the wild type
mice (p=O.OI7; Fig 3.2). In the 11 month cohort, a similar reduction in hq carrier A-wave
of approximately 25% was also apparent (p= 0.007; Fig 3.2). The largest effect on the Awave occurred at 15 months of age, corresponding to a drop of 40% in hq carrier A-wave
amplitude in comparison to the wild type (p<0.001; Fig 3.2). Left and right eyes were
not significantly different for both cr-wave and A-wave amplitudes. Age had a significant
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Figure 3.1. /!(/ genotype was confirmed post mortem using PCR amplification. A if
genotyping PCR amplicons were electrophoresed through a 1.5% agarose gel. A 725 bp
PCR amplicon indicates the presence of the hq proviral insertion into the A if gene. A 537
bp PCR amplicon is the result of the wild type A if gene without the proviral insertion.
The heterozygotes for the A if insertion, hq carrier mice, display both 725 and 537 bp
amplicons. Track-It™ 100 bp DNA ladder (Invitrogen, Burlington, ON) was used to
estimate fragment size. Negative controls were created by adding ddH20 to the PCR
master mix instead of DNA.
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Figure 3.2. Electroretinograpliy indicates early and progressive bipolar cell
functional losses, followed by late photoreceptor functional deficits at 15 months of
age in hq carrier mice. (A) a-wave amplitude is a measure of photoreceptor function.
The greater the negative value, the greater the photoreceptor response to the light
stimulus.

Although the harlequin carrier mice did appear to have reduced o-wave

magnitude when compared to wild type controls, this relationship was only statistically
significant at 15 months of age when there was a 39% drop from wild type values. (B) bwave amplitude, a measure of bipolar cell function, was 21% lower in 3 month-old
harlequin carrier mice than age-matched wild type controls.

Bipolar cell function

continued to decline up to 15 months of age hq carrier mice. In 11- and 15-month-old
cohorts, reductions of 25% and 40% in hq carrier ¿-wave amplitude were observed.
Sample size per cohort was six, and both left and right eyes were used to generate a- and
h-wave amplitude averages. Left and right eyes were not significantly different for either
a- or b-wave amplitudes.

Asterisks represent statistical significance (* p<0.05, **

p<0.01, *** p<0.001). Error bars represent +/- two standard errors of the mean.
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effect on a-wave and b-wave amplitudes as determined by Two-Way ANOVA (p= 0.014
and p<0.001) across both genotypes. Age-related changes in ERG amplitudes were
generally negative; however, inter-animal variation resulted in some positive fluctuation.

3.3 Optical Coherence Tomography (OCT) shows delayed retinal thinning
High resolution scanning of cornea, lens, and retina revealed no obvious anterior
obstructions or confounders to the imaging of retinal structure (Fig 3.3). Furthermore, no
qualitative evidence was found of microphthalmia, enophthalmy, angle closure, or cornea
and lens opacity which could account for the reduced visual function in any of the
cohorts studied. At 3 and 11 months of age, OCT measurements of retinal thickness were
not significantly different between hq carrier and wild type mice (Fig 3.3). However, at
15 months of age, a substantial thinning of the retina was detected in hq carrier mice
when compared to age-matched wild type mice (p= 0.006; Fig 3.3). The retinal thickness
of left and right eyes was not significantly different. Retinal thickness fluctuated between
age cohorts (p<0.001).

3.4 Hematoxylin and eosin retinal cell counts support late retinal thinning in hq carrier
mice
INL and ONL cell counts in the central retina revealed few differences in 3 and 11month-old mice. The only statistically relevant difference observed in these ages was
that the INL of 3-month-old hq carrier mice had 9% more neurons than wild type controls
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Figure 3.3. Optical Coherence Tomography (OCT) demonstrates retinal thinning in
15-month-old hq carrier mice and the absence of anterior segment pathology.
Anterior images of the 15-month-old wild type mouse eye (A), and the 15-month-old hq
carrier mouse eye (B) both indicated the absence of structural abnormalities. (C) Retinal
images of 15-month-old wild type mice were also absent of pathology. White arrows
indicate the neuronal retina (NR) and the retinal pigmented epithelium (RPE). Yellow
lines demonstrate the total central retinal thickness measurement incorporating both the
neuronal retina and the retinal pigmented epithelium. (D) In comparison to the 15month-old wild type retina, the age-matched harlequin carrier retina appeared thinned,
and less uniform in the superior neuronal portion of the retina. (E) The compiled total
retinal thickness measurements (n=6) from OCT imaging indicated no significant
changes in retinal thickness at 3 and 11 months of age. At 15 months of age, OCT
measurements revealed thinning of the harlequin carrier retina.
statistical significance (** p<0.01).

Asterisks represent

Left and right eye measurements were not

significantly different and were pooled in the analysis of retinal thickness data. Error
bars represent +/- two standard errors of the mean.

Age (Months)
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Figure 3.4. Central retina nuclear counts of the right eyes of 3-, 11-, and 15-monthold mice indicate thinning of the hq carrier ONL and INL at 15 months of age. (A)
Nuclear counts of the central retina were performed with 18 replicate measurements per
animal (n=3). The measurements taken from the INL indicated that at 3 months, hq
carrier mice (XhqX ) had 9% more INL neurons than wild type (WT) controls. There was
no significant difference at 11 months. At 15 months of age, there was a 16.4% reduction
in the number of INL neurons in comparison to wild type. (B) Measurements taken from
the outer nuclear layer indicated no significant differences between genotypes at 3 or 11
months of age.

However, at 15 months of age, the average number of nuclei in the

harlequin carrier ONL was reduced by 26% from wild type.

Asterisks represent

statistical significance (* p<0.05, ** p<0.01, *** p<0.001). Error bars represent +/- two
standard errors of the mean.

Central Inner Nuclear Layer Thickness (Nuclei)

Central Outer Nuclear Layer Thickness (Nuclei)

Age (Months)
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(p=0.038; Fig 3.4). In the 15-month-oid hq carrier cohort, central INL and ONL
thicknesses had respective deficits of 16.4% and 26% when compared to wild type
controls (p<0.001; Fig 3.4). Neuron counts in the peripheral retina did not display the
same trends, with the only significant difference between phenotypes occurring in the
ONL at 3 months of age (p=0.027; Fig 3.5) and the INL at 15 months of age (p=0.001;
Fig 3.5). This was likely due to innate differences in peripheral retinal thickness along
the dorsal-ventral and naso-temporal axes. Due to the absence of markers to standardize
directionality of the plane, large sampling variability between animals prevented
interpretation of peripheral retina thickness measures. Other than thinning of the INL and
ONL, there was no apparent evidence of retinal pathology in any cohort or region.
However, the abnormal placement of nuclei within the outer segment and outer
plexiformlayer may be evidence of retinal remodelling (Fig 3.6). Age was a statistically
relevant factor for both INL and ONL assessments in the central and peripheral regions
across both genotypes (p<0.001). Retinal counts of different scorers were not
significantly different.

3.5 Dihydroethidium (DHE) staining indicates increased superoxide levels in the hq
carrier retina
SOD substantially quenched DHE fluorescence, indicating specificity for
superoxide (Fig. 3.7). DHE fluorescence in the layers of the retina was consistently
higher in the 11-month-old hq carrier eyes than in age-matched wild type mice. Central
and peripheral ONL showed 24% and 19% elevations in hq carrier DHE fluorescence
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Figure 3.5. Peripheral retina nuclear counts of the right eyes of 3-, 11-, and 15month-old mice indicate peripheral ONL and INL thinning in 15-month-old hq
carrier mice. (A) Nuclear counts for the peripheral retina were performed with 12
replicate measurements per animal (n=3).

There were no significant differences in

measurements taken from the INL of 3- or 11-month-old mice. At 15 months, hq carrier
mice (Xlu'X) had 18.5% fewer INL neurons than wild type (WT) controls. (B) At 3
months of age, the average number of nuclei in the hq carrier ONL was 11% higher than
wild type controls.

Measurements taken from the ONL indicated no significant

differences between genotypes at 11 or 15 months of age. Asterisks represent statistical
significance (* p<0.05, ** p<0.01, *** p<0.001). Error bars represent +/- two standard
errors of the mean.
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Figure 3.6. Histology of 3-, 11-, and 15-month-old mouse retinas indicates the
abnormal retinal features in 11- and 15-month-old hq carrier mice (A) An image of a
10 pm thick, H&E-stained 3-month-old harlequin carrier retinal C-cut section.
Pathology was absent and there were no noticeable differences with (B) 3 month-old wild
type retinas.

(C) An image captured of the II-month-old harlequin carrier retina.

Although there were no significant differences in layer thicknesses with (D) 11 month
old wild type retinas, black arrows indicate the abnormal placement of nuclei in the outer
segment and outer plexiform layers not present in wild type controls. (E) Fifteen-monthold harlequin carrier retinas also contained these abnormally placed nuclei indicated by
the black arrows; however, this was also accompanied by a thinning of the outer and
inner nuclear layers as compared to (F) 15-month-old wild type controls.

O

n
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Figure 3.7.

Superoxide dismutase quenches dihydroethidium (DHE) staining,

indicating specificity for superoxide anions.

(A) A 10 pm thick section from 11-

month-old harlequin carrier mouse was treated with 50 pM DHE in DMSO.

DHE

fluorescence was visibly higher than the (B) 11 month-old wild type controls. (C) In
order to test DHE specificity for endogenously-derived superoxide anions, retinal
sections were pre-incubated with 30 U of bovine superoxide dismutase prior to DHE
exposure.

Specificity for superoxide anions was shown through the substantial

quenching of DHE fluorescence.
autofluorescence in retinal samples.

(D) DMSO-treated controls revealed minimal
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when compared to the wild type (p<0.001; Fig 3.8). Whole retinal analysis of the 1NL
and the GCL found respective 8.5% and 7.5% increases in hq carrier DHE fluorescence
(p=0.003 and p=0.006; Fig 3.8). Regional DHE fluorescence measures were not
significantly different between scorers.

3.6 Retinal function in 7-week-old hq disease mice is not significantly compromised
The «-wave, a measure of photoreceptor function, was not significantly different
in 7-week-old hq disease and wild type mice (n=5) (Fig 3.9). Similarly, h-wave
amplitude measures, a gauge of bipolar cell function, were not significantly different
between 7-week-old hq and wild type mice (Fig 3.9). Left and right eyes were equivalent
for «-wave and h-wave measurements across both genotypes.

3.7 Whole retina and cerebellar RNA was o f sufficient quality fo r transcriptional analysis
Bioanalyzer spectra were examined for evidence of RNA degradation and
genomic DNA contamination (Fig 3.10). Although cerebellar samples had clear
separation of I8S and 28S rRNA peaks, retinal samples included an additional peak
between the 18S and 28S (Fig 3.10). However, this peak was too well defined to be
either RNA degradation or genomic DNA contamination and so retinal samples which
passed all other qualitative and quantitative assessments were selected for microarray
analysis. RNA samples were simultaneously assessed for RNA quantity and only samples
with a concentration greater than 50 ng/pL were used (Appendix B: Table B.2).
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Figure 3.8.

Dihydroethidium (DHE) staining for superoxide anions in left-eye

retinal sections of 11-month-old mice indicates an increase in superoxide anions.
(A) Twelve central and twenty-four peripheral DHE fluorescence measurements were
taken in the ONL, INL and GCL of each mouse (n=6). The central and the peripheral
ONL showed 24% and 19% elevations in harlequin carrier (XhqX ) DHE fluorescence
over the 11 month-old wild type (WT) controls. (B) Pooling of central and peripheral
data indicated 8.5% and 7.5% elevations in harlequin carrier INL and GC fluorescence.
Asterisks represent statistical significance (* p<0.05, ** p<0.01, *** p<0.001). Error
bars represent +/- two standard errors of the mean.
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Figure 3.9. Retinal function of 7-week-old hq disease mice was not significantly
different from that of wild type mice.

(A) The a-wave amplitude, a measure of

photoreceptor function, was not significantly different between 7-week-old hq disease
and wild type mice (n=5). Left and right eye a-wave values were equivalent. (B) The hwave amplitude, a measure of bipolar cell function, was not significantly different
between 7-week-old hq disease and wild type mice (n=5). Left and right eye a- and bwave amplitudes were equivalent, and were averaged in the analysis.
represent +/- 2 standard errors of the mean.

Error bars
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Figure 3.10. Electropherograms indicate RNA quality for samples of both retinal
and cerebellar origin. (A) An electropherogram of retinal RNA generated using the
Agilent 2100 Bioanalyzer [Agilent Technologies Inc., Palo Alto, CA], Black arrows
indicate genomic DNA and RNA degradation products. The bar on the right of each
electropherogram is a simulation of agarose gel electrophoresis based on Bioanalyzer
data.

(B) An electropherogram of retinal RNA extracted from a wild type male

euthanized at 4 months of age. The 18S rRNA peak is labeled in pink; however, the 28S
rRNA is eclipsed by a larger peak of unknown identity. As a result, the automatic
labeling of the 28S rRNA by the Agilent 2100 Bioanalyzer has erroneously marked this
unknown peak in green as part of the 28S peak. (C) An electropherogram of cerebellar
RNA from the same animal. Note the clear separation of 18S and 28S peaks which was
not observed in retina.

A

C
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3.8 Limited differential gene expression in 5-week-old hq disease and wild type retinas
Using the criteria o f greater than or equal to 2-fold change in expression and less
than a p-value o f 0.05, only three genes were found to be differentially expressed (one of
which being the -3.76 fold downregulation of Aifml). Substantial loosening of the
selection criteria to fold changes greater than or equal to 1.5 still yielded only five genes
(Table 3 .1). Pathway analysis was not feasible for the small number of differentiallyexpressed genes.

3.9 Differential expression o f ECM remodelling, cell stress, and inflammation-related
pathways in 4-month-old hq disease retinas
Using selection criteria of greater than or equal to 2-fold change in expression and
a p-value less than 0.05, 270 genes were found to be differentially expressed: 85
downregulated and 185 upregulated in the 4-month-old hq disease retina compared to the
age-matched wild type retina (Appendix C: Table C.l). KEGG pathway analysis of the
270 differentially-expressed genes revealed a number of trends in the data (Table 3.2).
Pathways involving extracellular matrix (ECM) receptor interaction, focal adhesions, p53
signalling and the regulation of the actin cytoskeleton had a statistically significant
proportion of differentially-expressed genes (p<0.05). All of the pathways above
contained genes of interest for ECM remodelling, cell stress and cell migration. A
number of pathways involving cancer were present in the analysis, with many of the
differentially-expressed genes within these pathways belonging to the p53-mediated
stress response and DNA repair mechanisms.
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Table 3.1. Differentially-expressed genes between 5-week old hq disease and wild
type retina/*
Gene
Symbol

Gene Name

Fold Change

p-Value

Mela

Melanoma Antigen

9.88

<0.001

Aifml

Apoptosis-Inducing Factor

-3.76

0.002

Egri

Early Growth Response 1

-2.77

0.004

Xlr3b

X-Iinked lymphocyteregulated 3B

-1.71

0.021

Stfal

Stefin A 1

1.72

0.040

T T -rrT —

.

?_

r»

.
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^

[Partek Inc., St. Louis, MO], Selection of a differentially-expressed gene required greater
than a 1.5 fold change and less than a 0.05 p-value.
*Gene order was determined by ascending p-value.

6 8

Table 3.2.

KEGG pathway analysis of genes differentially expressed between 4-

month hq disease and wild type retinal samples/

Pathway

KEGG#

p-Value

Genes/Total
in Pathway

ECM receptor interaction

04512

4.7x10'6

9/81

Focal Adhesion

04510

1.7x10'4

11/199

Small Cell Lung Cancer

05222

6.2x10'4

7/94

P53 Signalling

04115

1.1 xlO'3

6/74

Pathways in Cancer

05200

3.1 xlO'3

12/339

Regulation of Actin Cytoskeleton

04810

5.2x1 O'3

9/213

ABC Transporters

02010

0.010

4/42

Autoimmune Thyroid Disease

05320

0.037

4/81

Analysis was performed using Pathway Express from the Onto-Tools Suite [Intelligent
Systems and Bioinformatics Laboratory, Wayne State University, Detroit, Ml].
^Pathway order was determined by ascending p-value.
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Manual annotation of the differentially-expressed genes (Appendix C: Table C.l)
yielded a number of genes of interest, specifically related to mitochondrial stress,
inflammation, and extracellular matrix remodelling. Candidate genes were then selected
for Taqman® qPCR validation (Table 3.3).

3.10 Differential expression o f inflammation-related pathways in 4-month-old hq disease
cerebella
The total number of differentially-expressed genes in the cerebellum was
substantially lower than in the retina, with only 39 genes under the pre-defined selection
criteria of minimum 2-fold change in expression and a p-value less than 0.05 (Appendix
C: Table C.2). In order to gain more robust relationships from pathway analysis, the
fold-change selection criteria was lowered to greater than 1.5 fold changes (p<0.05).
This yielded 199 differentially-expressed genes for analysis (Appendix C: Table C.3).
Pathway analysis identified significant gene expression changes within the complement
and coagulation cascades, hematopoietic cell lines, cytokine-cytokine receptor
interactions, cell adhesion molecules, systemic lupus erythematosus, leukocyte
transendothelial migration and antigen presentation and processing pathways (Table 3.4).
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Table 3.3. Functional annotation of genes of interest from 4 month retinal
microarray data. *
Gene

ID

Gpd2
Aldh2
Trpm6
Fnl

Functional
Mitochondrial
Stress
Mitochondrial
Stress
Mitochondrial
Stress
Ff’M

Component

Lama2

ECM
Component

Mertk

Cell Stress

Xdh

Cell Stress

Cdknla Cell Stress
H2-kl

Inflammation

B2m

Inflammation

Gfap

Inflammation

Ctss

Inflammation

Nos2
Aifml

Inflammation
Standard

Annotation
An oxidoreductase upregulated in a high glycolysis
environment, contributes to oxidative stress.
Ubiquitous enzyme involved in mitochondrial
aldehyde metabolism.
Upregulated with glucose metabolism-related ROS,
linked to calcium influx and monocyte activation.
ECM component which increases cell migration,
and is often upregulated during astrocyte and
microglial activation.
A basement membrane component involved with
blood vessel structure and oligodendrocyte
maturation in the brain.
A tyrosine kinase responsible for activation of
phagocytosis of damaged outer segment
components.
Upregulated by inflammatory cytokines. Creates
ROS through purine metabolism.
Upregulation causes cell cycle arrest in response to
cellular stress.
Part of the major histocompatibility complex 1
involved with inflammation, and associated with
synaptic plasticity.
Part of the major histocompatibility complex 1
involved with inflammation, and associated with
synaptic plasticity.
Upregulated in the activation of astrocytes and the
hypertrophy of Müller glia in response to
hyperglycaemia.
Lysosomal protease upregulated by microglia
during inflammation and aging.
Upregulated in microglia after metabolic insult.
Downregulated due to harlequin insertion.

Reference
110-111
112
113
114

115-116

117
118
119
120

120

83,121
122

123
98
'Annotation was based on Pubmed [National Institute of Health, Bethesda, MD] literature

surveys using the gene name in combination with other keywords such as
“mitochondria”, “retina”, “neuron” and “inflammation”
*Gene order was established according to functional category
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Table 3.4. KEGG pathway analysis of genes differentially expressed between 4month hq disease and wild type cerebellum samples/*

Pathway

KEGG#

p-Value

Complement and Coagulation Cascades

04610

1.6x10‘7

Genes/Total
in Pathway
9/74

Hematopoietic Cell Lines

04640

8.7x1 O’6

8/86

Cytokine-Cytokine Receptor Interaction

04060

7.9x1 O'5

11/249

Cell Adhesion Molecules (CAMs)

04514

2.1 xlO'3

7/159

Focal Adhesion

04510

9.7 xlO’3

7/199

Systemic Lupus Erythematosus

05322

0.019

5/181

Leukocyte Transendothelial Migration

04670

0.019

5/119

Antigen Presentation and Processing

04612

0.036

4/100

+Analysis was performed using Pathway Express from the Onto-Tools Suite [Intelligent
Systems and Bioinformatics Laboratory, Wayne State University, Detroit, Ml].
* Pathway order was determined by ascending p-value.
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3.11 Taqman E qPCR confirms differential expression o f candidate genes
O f the 14 genes assayed using Taqman“ qPCR, all 14 showed the same
directionality of gene expression change in comparison to the microarray, with thirteen
being upregulated, and one being downregulated in harlequin mice (Fig 3.11). Foldchange values were also highly correlated between microarray and qPCR assays
(Pearson’s coefficient = 0.850), with qPCR showing slightly larger fold changes than the
microarray (Fig 3.11). The majority of genes assayed also showed significant differences
according to the repeated measures ANOVA (Table 3.5). Despite appropriate foldchanges, the expression of two of the genes, Trpm6 and Lama2, was not statistically
different between harlequin and wild type mice.

3.12 Purity and quantity o f cerebellar mlDNA preparations
To determine whether mtDNA samples contained nuclear DNA contamination,
A if genotyping PCR was performed on all mtDNA samples. PCR using this tri-primer
method results in the formation of a 537 bp amplicon in the presence of the wild type A if
gene and a 725 bp amplicon in the presence of the A if proviral insertion. Presence of
either amplicon indicates a high likelihood of nuclear DNA contamination (Fig 3.12).
Only samples which did not yield amplicons as a result of^//P C R were used in random
mutation capture assay. Concentration of mtDNA samples was also determined
spectrophotometrically prior to use (Appendix B: Table B.3). Minimum concentrations
of approximately 80 ng/pL were required for downstream mutational analysis.
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Figure 3.11. Taqman qPCR fold-change data are highly correlated to Affymetrix
Mouse Gene 1.0 ST“ array fold-change values in 4-month-old mouse retinal
samples. (A) Fold-change calculations were made for 14 genes by normalizing to Gapdh
expression using the AACt method.

These values were compared to fold changes

obtained from microarrays using Partek Genomics Suite v6.5 [Partek Inc., St. Louis,
MO], Directionality and magnitude of fold-change values were similar between qPCR
and microarray techniques. (B) Pearson’s Correlation between microarray and qPCR
fold-change values was determined using SPSS version 16.0 [IBM Corporation, Somers,
NY], Correlation between microarray and qPCR was relatively high (r=0.850), with the
largest differences resulting from slightly higher fold-changes in qPCR.

hOT-

-6.0H

qPCR Fold Change in Expression
(//</ DiseaseAVild Type)
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Table 3.5. The statistical significance of differential expression of genes of interest
using both Affymetrix Mouse Gene 1.0 ST arrays and Taqman “ RT-PCR.+i

Gene ID

Mouse Gene 1.0 ST Array (p-Value)

Taqman® RT-PCR
(p-Value)

Gpd2

0.039

0.007

Aldh2

0.045

0.019

Trpm6

0.043

0.054

Fnl

0.017

0.033

Lama2

0.012

0.277

Mertk

0.015

0.013

Xdh

0.006

0.012

Cdknla

0.046

<0.001

H2-kl

0.037

0.002

B2m

0.037

0.001

Gfap

0.140

0.004

Ctss

0.050

0.040

Nos2

0.031

0.025

Ai f m l

<0.001

<0.001

TTT"------------1 Data were analyzed using PartekKGenomics Suite™ v6.5 [Partek Inc., St. Louis, MO]
1

1

•

.

1 (R ) ^

^

r

r r

and SPSS version 16.0 [IBM Corporation, Somers, NY] respectively.
* Gene order was established according to functional category
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Figure 3.12. Nuclear DNA contamination was assessed using A if genotyping PCR.
A if genotyping PCR was used to determine the presence of nuclear DNA contamination
in mtDNA samples. The presence of an amplicon indicated nuclear DNA contamination
in mtDNA samples. Only mtDNA extractions which failed to produce the A if amplicons
were selected for random mutation capture assay. Standard DNA extractions were used
as positive controls for PCR functionality.
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3.13 Random Mutation Capture indicates very low levels o f mitochondrial deletion in the
harlequin cerebellum
Throughout 19 random mutation capture runs, very few deletion mutants were
identified. Out of 1.84 billion copies of the mitochondrial genome screened, only two
mitochondrial deletions were identified in the hq cerebellum (Table 3.6) (Appendix B:
Fig B.3). Similarly, out of 1.47 billion copies of the mitochondrial genome screened,
zero deletion mutants were identified in wild type cerebella.

3.14 Random mutation capture has a high degree o f sensitivity
In order to validate the accuracy of the low incidence of deletions detected using
random mutation capture, a known deletion mutant was amplified and added to a mtDNA
sample. To determine the initial concentration of the amplified mutant, a 10-fold
dilution series was created and re-amplified using SYBR qPCR. Upon completion of a
standard curve, it was determined that a 100000-fold dilution of the original sample
contained approximately 50 mutant amplicons per reaction, or approximately 25
amplicons per pL (Fig 3.13). From this dilution, 2 pL, or approximately 50 mutant
amplicons were added to a low and a high concentration sample of mtDNA. Copy
number quantification of the low concentration sample indicated approximately 250000
mtDNA copies per pL. Copy number quantification of the high concentration sample
indicated approximately 850,000 mtDNA copies per pL. Both mtDNA copy number
values were extrapolated from dilution curves due to poor amplification efficiency in the
highest concentrations of the dilution series.
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Table 3.6. The frequency of mitochondrial deletions in relation to the number of
mitochondrial copies screened for 1.5 month-old hq disease and wild type eerebella.1
Mouse
Identifier

Aif
Genotype

Age
(Months)

Replicates

Copies
Screened

Deletions
Confirmed

False
Positives

AO 1.66

WT

1.6

4

6.0 xlO7

0

22

A01.55

WT

1.5

3

1.4 xlO9

0

5

A01.75

X hqY

1.6

3

2.6 xlO7

1

17

1.6

3

1.3 xlO7

1

21

1.5

3

9.7 x10s

0

4

A01.78
918.6

X hqY
XhqY

X hqY
918.3
1.5
3
8.4 x10s
0
4
IT. . ----'Mutations were selected for using the random mutation capture assay. Candidate
mutations were then re-amplified and sequenced to eliminate false positives.
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Figure 3.13. Quantification of a known deletion mutant by SYBR qPCR. A deletion
mutant detected by random mutation capture was amplified by PCR.

In order to

determine the initial concentration of the amplified mutant, a 10-fold dilution series was
created and re-amplified using SYBR qPCR on a Rotor-Gene 3000 [Corbett Research
Ltd., Sydney, Australia]. A standard curve was generated from this qPCR based on the
PCR cycle number at which each dilution reached the threshold of detection (Cj). Using
this method, it was determined that a 100000-fold dilution of the original sample
contained approximately 50 mutant amplicons per reaction, or approximately 25
amplicons per pL.
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Mutation detection in the resulting random mutation capture assays occurred at
high frequency, with 60/60 qPCR reactions detecting the known mutant in the low
concentration mtDNA sample, and 59/60 detecting the known mutant in the high
concentration mtDNA.
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Chapter 4 —Discussion
4.1 The hq carrier mouse shows compromised retinal physiology before neuron loss
Electroretinography of hq carrier mice revealed an early deficit (detectable at 3
months of age) of b-wave amplitude, corresponding to a reduced bipolar neuron response
to a light stimulus. This early reduction in retinal function was not observed at the level
of the photoreceptors, as o-wave amplitude and ONL thickness were only significantly
different between hq carrier and wild type mice at 15 months of age. The combination of
these electroretinography markers indicates that hq carrier retinal function is
compromised downstream of the photoreceptors in the ONL, pointing to pathology either
at the photoreceptor-bipolar cell synapse, or within the bipolar cells themselves.
Upon examination of retina structure, it was observed that 1NL and ONL neuronal
loss and subsequent retinal thinning did not occur until much later in the hq carrier
lifespan (15 months of age). Therefore, the pathological events triggering the early
decreases in bipolar neuron function were not apparent at the histological scale,
suggesting the presence of more subtle changes in bipolar or photoreceptor cell
morphology and/or physiology. This function before structure mechanism was also
observed in hq disease mice, however, with accelerated progression.104

4.2 Structured losses in the retina ofhq models mimic those o f normal mammalian aging
Extensive retinal phenotyping of both hq disease104 and carrier models indicate
that structural deterioration occurs primarily in the photoreceptors of the ONL. This
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finding is particularly relevant to normal aging mechanisms of the retina. In humans,
photoreceptors, specifically rod photoreceptors, decline 20-30% with age.” A recent
study of the rod dominated mouse retina found similar losses of approximately 40%.124
The majority of the rods lost in the aging mouse retina are distributed in the central
retina, which is also the case in hq models.124 Another shared feature of aging and hq
retinal phenotype is the accumulation of nuclei in the plexiform and photoreceptor outer
segment regions.

As such, it appears that hq retinal degeneration closely follows

normal mouse and human aging pathology.

4.3 The retina o f the hq carrier mouse shows mitochondrial dysfunction
Assessments of reactive oxygen species, specifically the superoxide anion, found
increased levels in all nuclear layers of the hq carrier retina when compared to agematched WT. This observation contrasts previous DHE data indicating no significant
difference between hq disease and wild type retinal superoxide levels.104 However, this
contradiction may be a technical artefact of the mechanism of DHE action. DHE is a
chemically reduced form of ethidium bromide. When it is oxidized by the superoxide
radical, it forms the fluorescent ethidium complex by intercalating with DNA.126 Due to
the localization of the fluorescence within nuclei, measurements of mean fluorescent
intensity can be skewed by altered nuclear density. In the case of the hq disease retina,
the rapid loss of neurons and the disorganization of the retinal layers104 could create an
abnormally low nuclear density, resulting in lower than expected mean DHE
fluorescence. Previous phenotypic characterizations of hq disease mice have shown
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increased oxidative stress levels as evidenced by increased ROS-induced DNA adducts
such as 8-OHdG and increased lipid hydroperoxide in cerebella.98 The sum of this
evidence indicates a strong possibility that superoxide levels are increased and that
mitochondrial dysfunction does exist prior to neuron loss in the hq mouse.

4.4 The challenges and limitations o f retinal phenotyping in the mouse eye
The regional specificity of retinal phenotyping is a major hurdle for the
examination of mouse eye, which is approximately 3.4 mm in diameter.127 For example,
the Colordome Stimulator [Diagnosys, Lowell, MA] electroretinography apparatus is
limited to measuring the retinal function of the full visual field, combining both
peripheral and central measures, due to the small surface of the mouse cornea. However,
the most difficult aspect of mouse retinal phenotyping in this study was the structural
comparison of similar retinal regions. As a corollary of histological examination of the
retina, it was noted that peripheral regions of the retina displayed a high degree of
variability in terms of morphology and neuron counts. These regional differences were
apparent even within single sections of the same retina. A factor which may contribute to
this variability is the orientation of the retinal sections along either dorsal-ventral or
nasal-temporal axes. During tissue processing, the enucleated eye is allowed free rotation
and there are no discernible features which can re-establish the original orientation.
Furthermore, OCT is incapable of imaging the peripheral retina, and cannot be used as a
standard for comparison. Hence, differences observed within the peripheral retina are
possibly the result of mixed orientations, thus limiting interpretation. Similar problems

exist with OCT and H&E assessments of the central retina, with regional photoreceptor
differences between superior and inferior regions.128 The alignment of cross-sections at
the vertex of the cornea (in OCT) or the optic nerve (in H&E) was performed to reduce
variability in these central retinal layer measures, although, it remains possible that
regional variation and section orientation may have influenced retinal cell counts. This
type of variation could potentially explain anomalous results such as the greater initial
amount of central INL neurons in 3-month-old hq carrier mice.

4.5 No functional deficits are apparent in seven-week-old hq disease mice
Previous characterizations of hq disease retinal function have indicated that retinal
function was unchanged at 5 weeks of age,98 and reduced at 8 weeks of age.104 To ensure
that this was the case, retinal function was assessed in 7-week-old mice. As predicted,
there was no significant difference between hq disease and wild type retinal function.
The absence of retinal deficits in the older 7-week-old hq disease mice suggests a high
likelihood of normal retinal function and physiology in the 5-week-old cohort, an
important preliminary finding prior to the gene expression analysis of the 5-week-old hq
disease retina.

4.6 Gene expression is largely unchanged in the retina o f 5-week-old hq disease mice
Very few gene expression changes were observed in the 5-week hq retina when
compared to wild type. Aifml, the downregulated gene in the hq phenotype, was
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confirmed as having transcript levels reduced by 74% in hq mice. Combined with
evidence showing that the 5 week retina is phenotypically normal,98 this suggests that A if
deficiency in the hq mouse does not influence retinal development. The hq retinal
disease mechanism appears to affect primarily the adult retina, potentially mimicking the
chronic accumulation of damage observed in normal aging and aging-associated diseases.

4.7 Gene expression analysis o f 4-month hq retina shows evidence o f altered metabolism
O f the 270 genes differentially expressed between the 4-month-old hq disease and
age-matched wild type retina, 83 genes are related to metabolic processes. This
approximate ratio is also maintained in gene expression analysis of the cerebellum, with
10 genes of 39 relating to metabolism. A number of these differentially-expressed genes
are also relevant to the OX-PHOS complex I deficiency in hq mice. Glycerol-3phosphate 2 (GPD2) is a protein which has been shown to oxidize glycolysis-derived
NADH and shuttle electrons to Coenzyme Q (downstream of complex I) of the OXPHOS chain.

In the process, it has also been shown to increase the generation of ROS

both in mitochondria and the cytosol.130 GPD2 has been shown to be upregulated in
environments of high glycolysis,11" presenting a potential link between compromised
OX-PHOS complex I, increased glycolysis and maintenance of NAD+ levels. Transcript
levels of Transient receptor potential cation channel subfamily M member 6 (Trpm6)
were also significantly upregulated in the hq retina. TRPM6 is a magnesium ion channel
which is upregulated in response to ROS from increased glucose metabolism." ’
Similarly, Pyruvate dehydrogenase complex component X (Pdhx), the link between
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glycolysis and Kreb’s cycle is dovvnregulated in the hq retina. Downregulation of Pdhx
has also been demonstrated in the presence of high intracellular glucose and lipid
levels.1*' Finally, Aldehyde dehydrogenase 2 (Aldh2) is the major eliminator of toxic
aldehydes within the cell and is upregulated in the hq retina. Aldehydes are generated as
a by-product of glycolysis and, if left to accumulate, can cause the glycation of amino
acids.

The differential expression of these various markers related to glycolysis,

combined with previous evidence of OX-PHOS complex I deficiency," suggests that
glycolysis may be compensating for reduced OX-PHOS activity.

4.8 Transcriptomes o f the retina and cerebellum ofhq disease mice indicate
inflammation
Pathway analysis of differentially-expressed genes in both 4-month retinal and
cerebellar yielded a number of pathways involved with inflammatory processes. Auto
immune thyroid diseases may have been the only statistically significant pathway in the
retina, but complement and coagulation cascades, hematopoietic cell lines, cytokinecytokine receptor interactions, cell adhesion molecules, systemic lupus erythematosus,
leukocyte transendothelial migration, and antigen presentation and processing all
represent significant pathways related to inflammation and immunity in the cerebellum.
However, this low representation of inflammatory pathways in the retina is likely due to
the fact that the KEGG database does not have specific pathways for neuroinflammation
or retinal diseases. Manual annotation of differentially-expressed genes in the 4-monthold retina identified a number o f genes with very specific functions in retinal
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inflammation. One example o f this is the increase in expression of Cluster o f
differentiation 6H (Cd6H), a surface antigen for activated microglia or any macrophagelineage cells,1" in the hq retina. Furthermore, increased expression of MHC I
components Beta-2-microglobulin (B2m), Histocompatibility 2-Kl (H2-kl), and
Histocompatibility 2-D1 (H 2-dl) is also specific to microglial activation.134 A marker of
the potentially negative consequences o f inflammation is an increase in expression of
•

Inducible Nitric Oxide Synthase (Nos2). Nos2 is upregulated in activated microglia,

ill

but Aoi-2-derived nitric oxide is generally associated with inflammation-mediated
neurotoxicity.41 The upregulation of all of these microglia-specific markers suggests the
presence of activated microglia within the hq disease retina.
In terms of markers of astrogliosis, two astrocyte markers. Aldehyde
dehydrogenase 1L1 (A ld h lll) and Gfap were both upregulated in the hq retina.135 In
response to inflammatory cytokines, astrocytes are also known to increase transcript
levels offibronectin (Jhl) and laminin components (Lama2, Lama3, Lamc2).' '6 The
upregulation of fibronectin and laminin has been shown to have a multitude of
downstream effects, including increased vasculogenesis,x> increased microglial
activation1'7 and increased neurite outgrowth and regeneration.138 The upregulation of
these astrocyte-specific markers indicates a reasonable likelihood of astrocyte activation.
The presence of microgliosis and astrogliosis could be confirmed through
immunohistological assays for the F4/80 antigen and GFAP which are specific markers
of active microglia21 and astrocytes,135 respectively
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4.9 Transcriptional and histological evidence supports extracellular matrix remodelling
in hq disease retinas
The two most prominent pathways identified in the hq retina were related to ECM
receptor interaction, and focal adhesions (involved with the regulation of ECM and
cytoskeletal elements). These pathway analysis results, combined with differential
expression of a variety of matrix fibres (Fibronectin, Tenascin-X), basement membrane
components (Collagen, Laminin, FRAS1 related extracellular matrix protein 2) and ECM
reorganization genes (Heparin sulphate-degrading enzyme) indicate a strong possibility
of ECM remodelling in the hq retina. H&E stained sections of hq carrier retina, also
support the hypothesis of ECM remodelling with the presence of abnormalities in nuclear
placement and disruption of the laminar shape of the retinal layers (Fig 3.5). Similar
abnormalities were observed in previous characterizations of the hq disease retina.104

4.10 Evidence fo r neurite remodelling in the hq disease mouse
Another trend identified by pathway analysis is that of altered expression of actin
cytoskeleton components. Although this is a broad category, many of the genes within
this pathway are specific to regulation of actin in neurites. IQ m otif containing GTPase
activating protein (Iqgap3) and Moesin (Msn), which are responsible for the organization
of actin’39 and the interaction of actin with the plasma membrane in the distal portion of
axons,140 respectively, were both significantly upregulated. Contrasting this trend is the
downregulation of triple functional domain (Trio) in the hq retina (Trio is also a positive
regulator of neurite outgrowth through actin dynamics)141 and Roundabout homolog 3
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(Robo3), a gene involved in axon guidance in the retina.142 Further investigation of
neurite-related genes revealed an upregulation of several genes involved with the
maintenance of neurites and synapses such as Sodium channel beta 4 subunit (Scn4b),
Sterile alpha m otif domain containing 4 (Samd4), and Sidekick-2 (Sdk2). Scn4b is a
subunit of type IV voltage-gated sodium channels which is linked to neurite
maintenance,14' whereas Samd4 is a translational regulator of neuronal genes which
responds to synaptic activity144 and Sdk2 is a necessary component of the photoreceptor
synapse.145 The upregulation of extracellular matrix genes fibronectin and laminin is also
observed in hq disease retinas. Fibronectin and laminin are thought to have a permissive
effect on neurite outgrowth.138 However, despite the upregulation of these neurite
maintenance and growth-related transcripts, there is also the differential expression of
genes involved in neurite injury. The upregulation of Calpastatin (Cast) is of interest due
to its inhibitory function on the Calpain protease, which is the primary effector of
caspase-independent neurite degeneration.78 Upregulation of Parathyroid hormone
receptor (P thlr) has also recently been linked to axonal injury,141' although its function in
this context is still unknown.
Due to the complicated nature of pathways regulating neurite outgrowth,
conclusions regarding the state of neurites in the hq retina are precarious at best.
Although the directionality of the change in gene expression could lead one to infer that
the hq retina is in the process of creating or repairing neurites, the upregulation of neurite
maintenance genes could just as likely be a compensatory mechanism to protect
remaining neurites. Whether this particular set of genes is normally upregulated in
response to neurite damage or loss remains to be seen, as there has been no similar gene

92

expression studies performed in the mouse retina to date. Nevertheless, literature
regarding other neurons types found in the hq brain would suggest a high probability of
neunte degeneration as a result of mitochondrial dysfunction.I(l> Testing this specific
hypothesis of neunte degeneration could be performed in situ using the Fluoro-Jade B "
histochemical assay.147

4.11 Limitations o f transcriptome data in identifying disease mechanism
Although transcriptional data are useful to identify potential changes in gene
expression through transient changes in mRNA transcripts, there are a number of
limitations on such data. Transcriptional regulation is upstream of translational, and post
translational regulation, and therefore does not necessarily reflect the final levels of
protein quantity or enzymatic activity associated with the final gene product. It should
also be noted that with the high levels of redundancy and complexity involved in
mammalian systems, changes in expression within a single gene still may not have a
biologically relevant impact. However, this disclaimer aside, mass expression arrays are
still a very useful technology for identifying trends and generating hypotheses which can
later be assessed at the biochemical and histological levels. A similar hypothesis
generating strategy was employed in the elucidation of hq degeneration of olfactory
epithelium.148
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4.12 Mitochondrial deletions do not play a major role in the initiation o f cerebellar
degeneration
The levels of mitochondrial deletion in both hq and WT cerebella were extremely
low, making it impossible to make any genotype-based statistical comparisons.
However, the fact that the deletion frequency was so low requires either a biological or a
technical explanation. The literature frequency of mitochondrial point mutation for mice
1-3 months of age is 6-8 xlO"7 mutations/bp.7(l although, no universal literature value
exists for deletions detected by random mutation capture due to the regional nature of the
assay.76 The mutational target site, base pairs 8974-12116 of the mitochondrial genome
(NC 005089), corresponds in large part to the NADH dehydrogenase subunit 4 locus
(9877-11544). This particular region of the mitochondrial genome is prone to
deletions.149 However, the ability to detect mutations using the random mutation capture
assay is also based on the number of nucleotides between the PCR priming sites and the
Taqa] cut sites. For the primer set in use, this represents 605, and 26 nucleotides for
forward and reverse primers, respectively (Appendix B: Fig B.4). Based on a genome
size of 16299 base pairs, the odds of a deletion occurring within these primer sets are
approximately 1/16888 deletions (605/16299 * 26/16299). This factor is necessary in
order to extrapolate the deletion frequency to the entire mitochondrial genome. However,
even multiplying the current hq cerebellum deletion frequency by 16888 only yields a
frequency of 1.68 x 10° deletions/mitochondrial genome, which is far below the
approximate 70% homoplasmy threshold required for pathological consequences.66
Another factor which may have influenced the low deletion frequency is the age
and tissue examined. Mitochondrial deletions tend to accumulate in advanced age.150
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Although most somatic nuclear mutations occur from development to early adulthood,151
the replication of the mitochondrial genome occurs constantly throughout the lifespan of
the individual, allowing the constant creation of new mutations from damaged DNA,
even in post-mitotic tissues. A previous characterization of mitochondrial deletions in
brain tissue indicated a 25-fold increase from young to old mice.72 Therefore, the
utilization of tissue samples from young mice (1.5 month-old) may be responsible for the
low levels of mitochondrial deletions observed. Also of interest is the finding that
cerebellar mitochondria have a lower deletion frequency than other similar tissues of the
brain.150 This property o f cerebella has also been observed in the Nd4 locus.152 It has
been speculated that this low propensity for mitochondrial deletion may be a result of the
short cerebellar axonal projections. Short axons maintain an ionic gradient over a smaller
area, possibly resulting in fewer detrimental effects of metabolic insult.152 In any case,
this mutational resistance observed in the cerebellar mitochondrial genome is also
prevalent in the nuclear genome, with low levels of mutation extending to late
adulthood.151

4.13 Random mutation capture is sensitive to detection o f rare mutations
The random mutation capture sensitivity assay demonstrated a relatively high
sensitivity for the known mutant, with nearly all PCR reactions testing positive for the
mutation. However, there were a number of inherent biases with this sensitivity
assessment. The original quantification of mutant copy number, or at the very least, the
transfer o f the mutant copies to the rntDNA samples, was clearly inaccurate. Using a
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Poisson distribution, the average number of mutant copies per high mtDNA reaction was
estimated to be 4.1. This would place initial mutant copy total at nearly 250 instead of
the 50 copies expected. The source of this error could be due to a number of the
possibilities. It is possible that the viscosity of the mitochondrial DNA resulted in
heterogeneous dilutions in the 10-fold dilution series, a problem which would be
compounded by having only a single replicate of qPCR for the standard curve. Another
issue which may have resulted in an underestimation of the known mutant is the
amplification efficiency. Although a qPCR efficiency of 1.21 (equivalent to 79%) is
passable for most qPCR uses, lowered efficiency results in a delay in reaching the real
time PCR detection threshold, thus artificially increasing C j values and under
representing the total copy number. One or both of these factors could have potentially
influenced the calculation of mutant copy in the random mutation capture sensitivity
assay.
Another source of potential bias in the sensitivity assay was the use of previously
amplified mutant fragment. Amplification from a previous PCR template likely does not
represent the complexity of a genomic template due to the absence of flanking regions
which could potentially contribute to secondary structures, especially in a reaction which
is highly saturated with wild type mtDNA. Despite the robust detection of the mutant, it
is still quite possible that random mutation capture sensitivity is too low for the sparse
number of mutants in the samples examined.
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4.14 Mitochondrial deletion is an unlikely initiator ofhq neurodegeneration
Regardless of the possible confounding variables, it remains highly unlikely that
mitochondrial DNA plays a role in the initiation of the hq cerebellar disease phenotype.
Although tissue-dependent differences are quite frequent in mitochondrial mutation rates,
based on high similarity between retinal and cerebellar disease progressions, it is also
quite probable that mitochondrial deletion does not play a role in retinal disease initiation
either. However, further studies do need to be performed to determine whether
mitochondrial deletions do play a secondary role during the late stages of hq
neurodegenerative progression.

4.15 The hq models display multiple markers o f retinal aging
The neurodegeneration of the hq mouse does appear to have many of the
hallmarks of natural aging. The hq carrier mice display increased superoxide generation,
while hq disease mice have transcriptional markers of mitochondrial stress, as well as
complex I deficiency'5’ and increased oxidative adducts.^8 All of these features are
consistent with mitochondrial dysfunction, a well known consequence of aging.154' 155
Furthermore, hq retinal degeneration results in pathologies which are identical to those
found in aging, such as rod photoreceptor loss'” and abnormal nuclear placement.125 The
multiple markers of inflammation are also consistent with aging,156 as a recent report has
indicated microglial activation in the healthy aging brain.157 The presence of markers for
so many of aging-associated mechanisms indicates that the hq mouse is a realistic model
of premature aging, particularly in the context of neurodegeneration.
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4.16 Chronic light toxicity may drive ml dysfunction-dependent retinal degeneration
There are many parallels between the effects of light toxicity and aging in the
retina. Both light toxicity and aging result in photoreceptor (primarily rod)
degeneration,33 '4 microglial activation,24 127 and mitochondrial dysfunction.36 158 It has
also been demonstrated in rats that increased age results in an increased susceptibility to
light-induced photoreceptor loss.159 Considering the shared features of light toxicity,
aging, and hq models, it is possible that ambient light is an environmental factor in the
initiation, and/or the exacerbation of hq model retinal degeneration. Some of the first
pathological changes in photoreceptors exposed to acute light stress are the loss of
mitochondrial membrane polarity, accompanied by Ca2+ influx and superoxide
generation.36 Morphological changes occur within the first week after high light
exposure with the loss of photoreceptor synapses.160 The end result of these changes is
increased photoreceptor apoptosis and thinning of the ONL related to microglial
function.34 161162 These features of light stress are relevant to hq models. Elevated levels
of superoxide were identified in the hq carrier mouse. In addition, existing mitochondrial
dysfunction as a result of AIF deficiency" could potentially sensitize photoreceptor
mitochondria to membrane depolarization. Although there is no direct evidence of
synapse loss in hq models, disruption of synapses would correspond to the early
reduction in 6-wave (bipolar response) in the absence of bipolar or photoreceptor loss.
Finally, markers of microglial activation were upregulated in 4-month hq disease retinas,
a time point which corresponds to increased apoptosis of photoreceptors.104 Subsequent
thinning of the ONL was observed in hq carrier mice and in previous characterizations of
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hq disease mice.104 The close resemblance of these features is reasonable evidence that
light toxicity may play a role in hq photoreceptor degeneration.

4.17 The central hypothesis was supported by experimental data
The central hypothesis that functional deficits occur before anatomical and
histological changes in the hq carrier retina was supported by ERG, OCT and histological
methods. Furthermore, evidence of mitochondrial dysfunction was revealed through the
increased levels of superoxide in the hq carrier, and increased expression of genes related
to mitochondrial stress. Although no direct evidence of calcium release was discovered,
expression of genes related to neurite growth and maintenance was significantly altered
in hq disease mice. Gene expression assays also revealed increased transcript levels of
markers of glycolysis and inflammation. An alternate hypothesis of elevated frequency
of mitochondrial DNA deletions contributing to the initiation of granule neuron
degeneration was also undermined. Although further evidence must be gathered to
substantiate the contributing mechanisms o f hq retinal degenerative disease, the central
tenet of functional deficits preceding anatomical and histological alterations was
confirmed.

4.18 Conclusions
Because of the high fidelity between previously described aging markers and the
hq disease progression, it may be possible that other aspects of hq disease hold true in
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normal aging. In this case, deficits in retinal function preceding neuronal loss could be
an important facet of normal aging. Although this possibility has yet to be investigated in
human neurons, early functional screening using ERG could potentially open avenues for
preventative interventions and aging-associated disease management. Further studies,
both in animal models and humans, must be performed to examine the validity and
potential management of the function-before-structure mechanism of retinal
degeneration.
In terms of the initiation of age-associated changes in hq models, the connection
between mitochondrial dysfunction and light toxicity may be of interest. Both
mitochondrial dysfunction and light stress occur inevitably, either through metabolic
accumulation of damage or light exposure, respectively. Due to the similar features of
aging-associated mitochondrial dysfunction and light toxicity, it is conceivable that they
share a common mechanism in age-related photoreceptor degeneration. Studies
involving light deprivation and saturation in hq models would be of interest to
determining whether light levels can modulate the effects of mitochondrial dysfunctionrelated photoreceptor degeneration.
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Appendix A - The University of Western Ontario Ethics Approval for Animal Use in
Research
This appendix contains a copy of the ethics approval form for animal use in the Hill
laboratory from the University Council on Animal Care and the Animal Use
subcommittee.
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Appendix B - Supplementary Figures and Tables
This appendix contains supplementary figures and tables used to aid in understanding of
research presented within this study.
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Figure B.l. A conceptual diagram of the Taqman" qPCR experimental design. The
384-well plate is divided into rows and columns.

Each row represents a different

Taqman“ probe set for a specific gene of interest.

The columns are colour-coded

according to sample or no-template control (NTC). Each gene of interest is assayed in
triplicate for each mouse cDNA sample, and in duplicate forNTCs.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

917.98 X hqY
916.168 WT
917.97 X hqY
916.164 WT
AO 1.43 X hqY
AO 1.42 WT
NTC

A 1-20
B l-20
C l-20
D l-20
E l-20
F 1-20
G 1-20
H 1-20

Gpd2
Aldh2
Trpm6
Gapdh
Fnl
Lama2
Mertk
H 2-kl

11-20
J 1-20
K l-20
L I-20
M l-20
N l-20
01-20

B2m
Xdh
Aifm l
Gfap
Ctss
Nos2
Cdknla
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Table B.l. The list of primers utilized in PCR-based experiments
Target
M

Nd4 Deletion
Target

Rnrl
Mitochondrial
Copy Number

Primer
Position

Sequence (5’ to 3’)

Forward

CTATGCCCTTCTCCATGTAGTT

Reverse

AGTGTCCAGTCAAAGTACCGGG

Provirai
Forward

GAACAAGGAAGTACAGAGAGGC

Forward

CCTCCAACAGGAATTTCACC

Reverse

GGTGAGGATAAGCATGGTAATC

Forward

TCGGCGTAAAACGTGTCAAC

Reverse

CCGCCAAGTCCTTTGAGTTT

Length of
Amplieon (bp)
537 (WT)

725 (hq)
Deletion
size
dependent

248
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Figure B.2. Sample melt curves from SYBR qPCR indicating the markers of false
positive amplification in random mutation capture. (A) Upon completion of qPCR,
the Rotorgene 3000 [Corbett Research Ltd., Sydney, Australia] performs a melt analysis
of the produced amplicons by gradually increasing temperature while continuously
measuring SYBR fluorescence.

As amplicons melt into single-stranded DNA, the

SYBR-related fluorescence decreases readily.

Rotorgene“ software uses the relative

decrease in fluorescence to determine the melting temperature of the amplicon.
resultant melt spectrum for a true positive mutant is shown.

A

(B) Melting spectra

indicating low melt temperatures are often indicative of primer dimers. Another feature
of primer dimers is a wide range of melting, indicated by a wide peak in the melt
spectrum. (C) Another source of false positives in random mutation capture is wild type
mutation targets which were not cleaved during restriction digests. Due to the large size
of the resulting amplicons, melting can occur regionally. Regional differences in melting
temperature results in multi-modal melt peaks.

w

O

Change in Fluorescence per Second

Change in Fluorescence per Second

>

Change in Fluorescence per Second

Temperature (°C)
o

K)
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Tabic B.2. The concentrations of RNA samples extracted from retina and cerebellar
samples.
Sample
Identifier

Genotype

Age
(Months)

Retinal RNA
Concentration
(ng/pL)

Cerebellar RNA
Concentration
(ng/pL)

E01.10

X*Y

1.2

644

N/A

918.42

XhqY

1.2

198

N/A

919.5

XhqY

1.2

420

N/A

918.43

WT

1.2

513

N/A

919.3

WT

1.2

86

N/A

919.47

WT

1.2

169

N/A

917.98

XhqY

4.0

167

480

917.97

XhqY

4.0

50

305

AO 1.43

XhqY

4.3

114

448

916.168

WT

4.1

102

330

916.164

WT

4.1

149

314

AO 1.42

WT

4.0

116

328
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Table B.3. The concentrations of cerebellar mtDNA samples used in random
mutation capture.
Sample Identifier

Genotype

Age (Months)

mtDNA
Concentration
(ng/pL)

AO 1.66

WT

1.6

77

AO 1.55

WT

1.5

254

AO 1.75

hij

1.6

107

AO 1.78

hq

1.6

111

918.6

hq

1.5

286

918.3

hq

1.5

229
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Figure B.3. Mitochondrial deletions were confirmed by PCR re-amplification and
sequencing. (A) The re-amplification of suspected mutants yielded two amplicons, one
for the AO 1.78 D2 mutant (faint), and one for the AO 1.75 Cl mutant. PCR confirmations
were performed in duplicate. Water and a random mutation capture false positive were
used as negative controls. Identifiers D2 and Cl represent the original position of the
qPCR tube relative to the random mutation capture plate design. (B) Sequencing of the
D2 mutant revealed a substantial amount of homology with the wild type reference
sequence. Nucleotides highlighted in yellow were identical between sequencing runs and
the reference sequence from the mouse mitochondrial genome (NC 005089) Alignment
of sequences also revealed the specific location o f the deletion, spanning between basepair 9098 and 12115 of the mouse mitochondrial genome. Sequencing of the Cl deletion
was difficult due to poor efficiency.

Sequence matching of approximately 20% was

sufficient to confirm the mutant; however, no precise deletion breakpoint was identified
in the C 1 mutant.
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Forward Primer (8955-8974)
CCTCCAACAGGAATTTNNCC
CCTCCAACAGGAATTTCACC

D2 M u t a n t S e q u e n c e
Reference

Nd4 Deletion Locus (8975- 12115)
ACTTAACCCTCTAGAAGTCCCACTANTNNNNNNNNNNNNNNTCNAGCANNA
ACTTAACCCTCTAGAAGTCCCACTACTTAATACTTCAGTACTTCTAGCATCA
(9078)
[........JCNCATAAATCAAGCCCTACT
[........JCACATAAATCAAGCCCTACT

Reverse Primer (12116-12137)
GATTACNNNNNNNNTCCTCACC
GATTACCATGCTTATCCTCACC

Deletion Location
(9098-12115 bp)
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Figure B.4. The structure of the Nd4 deletion target locus used in random mutation
capture. Forward and reverse primers are located 605 and 26 nucleotides, respectively,
from the nearest Taqa\ restriction site (denoted by 5TCGA3’). In order for a deletion to
be detected, its break points must occur in both o f these regions. The probability of this
occurrence, assuming each base pair (bp) in the 16299 bp mitochondrial genome has an
equal probability of a double-strand break, is 1/16888. Therefore this particular deletion
target only captures 1 in every 16888 deletions o f the mitochondrial genome.
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Forward Primer
---------- >

TCGA
AG CT

TCGA
AGCT

TCGA
AGCT
Reverse Primer
26 bp

605 bp

Probability o f Deletion Adjacent Forward Primer:
__________ 605 bp_____________
16299 bp of Mitochondrial Genome

= ~ 1
30

Ratio of Total Deletions Detected by Target:
1
30

I
624

~ 1
16888 deletions
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Appendix C - Microarray Data Tables
The appendix contains a list of all differentially-expressed genes identified by
microarray, including manually annotated genes and those used in KEGG pathway
analysis.
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Table C .l. List of the genes differentially expressed in 4-month-old hq disease
mouse retinas.

Gene Sym
bol

p-Value

A ifm l

1.6E-04

Fold
Change
-6.01

Annotation
Involved inO
X
-PH
O
Scom
plex assembly
Cytochrome P450variant, downregulated during

Cyp3a25

3.1E-02

-4.69

Tecrl

2.1E-02

-4.14

He

1.2E-02

-3.91

T tc l8

2.5E-03

-3.43

Component of ciliated cells

Trim 36

2.8E-02

-3.41

M
icrotubule/cell cycle-associated protein

Abca6

4.5E-02

-3.09

Iqgap2

4.4E-02

-3.02

M yh6

5.9E-03

-2.90

S lc 4 a l0

2.7E-02

-2.87

Robo3

8.0E-04

-2.81

Olfm4

1.5E-02

-2.77

Haus6

3.6E-02

-2.71

endotoxin delivery, possiblythrough N
F-IL
6
U
nknown
Complement 5a - inflammatoryfactor related to
metabolism

Transporter involved with macrophage lipid
homeostasis
A
ctin remodelling inO
Sphagosome/endosome
transport
M
yosin heavychain (cardiac)
Na/HC03 and Cerebrospinal fluid transport, found
in retinal choroid
A
cts in neurite outgrowth
Induces early m
yeloid development in response to
R
O
S
Centrosome and spindle organization

Atm

3.6E-02

-2.69

D
N
ADam
age Response

N b rl

2.3E-02

-2.64

Involved inautophagy/ubiquitin proteasome

BC030307

6.0E-03

-2.63

U
nknown

Slc26a4

1.6E-02

-2.61

Chloride-Iodide transporter

D p y l9 ll

2.7E-02

-2.54

U
nknown

P p p lr9 a

1.5E-02

-2.53

4930519F16Rik

6.1E-03

-2.52

U
nknown

Hydin

4.6E-02

-2.52

Osmohomeostasis of ciliated cells (M
uller G
lia)

W dr60

7.1E-03

-2.51

U
nknown

D19Ertd652e

3.0E-02

-2.50

U
nknown

Pdhx

1.6E-02

-2.48

M
aintains dendrites via tethering of protein
128hosphatise 1to actin filaments

Pyruvate dehydrogenase
Aquaporin - downregulated after optic nerve

Aqp4

1.8E-03

-2.47

D n a h c ll

1.7E-02

-2.47

D
ynein heavy chain inciliated cells

P k d ll2

6.7E-03

-2.47

Polycystic kidneydisease

Siglece

3.2E-02

-2.46

Inhibits TLR-induced inflammation

injury
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BC055324

4.5E-02

-2.41

Unknown

G a rn ll

5.0E-02

-2.39

Involved inbrain development

S m c lb

4.7E-02

-2.38

Involved intelomere maintenace

4930519F16Rik

1.2E-02

-2.38

U
nknown

Klra5

9.4E-03

-2.37

Expressed in Natural K
illerT-cells

P e a rl

4.2E-02

-2.36

Platelet activation receptor
R
ho Guanine exchange factor involved in neurite

Trio

1.6E-02

-2.35

Ltbp2

3.4E-02

-2.34

Involved inT
G
F-Bsecretion and targeting

A dal

3.3E-03

-2.34

Unknown

Kmo

4.3E-02

-2.33

Lrrc9

4.6E-02

-2.31

Unknown

4922505G16Rik

3.8E-02

-2.30

Unknown

M a n scl

4.0E-02

-2.29

Unknown

Rbms3

1.1E-02

-2.28

RN
A
-binding protein

Golga3

3.9E-02

-2.28

G
olgi apparatus protein involved inapoptosis

C a rl

2.6E-02

-2.27

Hdc

8.8E-04

-2.24

Synthesizes histamine in retinal neurons

A n k fy l

1.6E-03

-2.24

M
ay be involved invesicle transport

M sh3

4.8E-03

-2.21

M
ism
atch repair protein downregulated incancer

Dnahc2

2.4E-02

-2.21

outgrowth

Involved intryptophan metabolismdownregulated ininflammation

Catalyzes C
02- bicarbonate reactions, linked to
retinal bloodflow

D
ynein motor protein - unknown function
Binds cytochrome Cto activate the apoptosome,

A p a fl

3.7E-02

-2.20

C o l7 a l

1.7E-02

-2.19

Basement membrane protein

Sall2

1.4E-02

-2.18

Promotes neurite outgrowth and development

Katnal2

3.1E-02

-2.18

Unknown

S lc 3 8 a ll

4.4E-02

-2.18

Sodium-coupled amino acid transporter

Col4a2

2.7E-02

-2.17

RPE-related collagen

Npy2r

2.1E-02

-2.17

Neuropeptide Yreceptor

Rad50

4.5E-02

-2.16

D
S
Brepair and telomere maintenance

Nm br

3.9E-02

-2.15

M
itogen and growth factor receptor

Tada3l

1.1E-02

-2.15

Transcriptional activator involved with p53

Nlrp3

3.4E-02

-2.15

Part of the inflammasome

Dhx29

4.0E-02

-2.15

Helicase involved in R
N
Atranslation

Col9a2

6.3E-03

-2.14

Basement membrane collagen

Duox2

5.2E-03

-2.11

Produces H
2
02
, dowregulated ininflammation

Wrn

5.0E-03

-2.11

Helicase involved inD
SBrepair

downregulated inaging G
C
L
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Pard3b

2.5E-02

-2.11

Involved incell polarity and tight junctions

Ptpru

8.6E-04

-2.11

C
ell adhesion positive regulator

Clasp2

4.8E-02

-2.09

M
itotic spindle organization
Glutamate receptor-downregulated in low

Grin2b

4.2E-02

-2.08

4921528l07Rik

3.8E-02

-2.06

Unknown

4921528l07Rik

3.8E-02

-2.06

Unknown

M s4a4c

1.9E-03

-2.06

Unknown

Tg

2.3E-02

-2.06

Thyroglobulin (thyroid hormone)

Itga8

3.3E-02

-2.06

N u d tl3

3.1E-02

-2.06

Unknown

Oca2

2.3E-02

-2.06

Tyrosine transporter in melanin synthesis

Itgal

1.3E-02

-2.06

M
icroglial cell adhesion, inflammatory response

2010204N08Rik

2.2E-02

-2.05

Unknown

Scn5a

1.9E-02

-2.05

Voltage-gated sodiumchannel

Spnal

1.1E-02

-2.04

Cytoskeletal component cleaved inaxonal injury

D p p lO

5.0E-02

-2.04

M
odulates potassiumchannel function

Coq7

1.8E-04

-2.03

R fc l

6.4E-03

-2.03

Role in replication, repair, telomere stabililty

Telo2

8.2E-03

-2.01

Involved inS-Phase checkpoint and D
N
Arepair

Nlrc5

1.6E-02

-2.00

Negative regulator of Interferon signalling

B rc a l

2.2E-02

-2.00

Regulates D
N
Astabilitythrough D
S
Brepair

K lk lb l6

2.5E-02

2.00

Unknown

Lam a2

1.2E-02

2.00

Lam
inin Component

A tp 8 b l

1.9E-02

2.00

A
TP-bindingtransporter

Baiap3

3.9E-04

2.00

Brain-specific inhibitor of angiogenesis

Igfbp3

3.6E-02

2.01

Linkedto angiogenesis, present inm
icroglia

Ddx60

2.0E-02

2.01

Unknown

Lm na

1.6E-02

2.01

Nuclear architecture protein - linked to aging

Ephxl

4.3E-02

2.01

Cleaves anti-inflammatory peptides

Scn4b

4.2E-02

2.01

Sam d4

3.2E-02

2.01

Translational regulator of synaptic proteins

C yfip l

2.1E-02

2.01

Involved inaxon outgrowth, interacts with Trio

Fbln2

5.7E-03

2.01

E
C
Mprotein, upregulated inretina detachment

Ankrd26

2.9E-02

2.02

Unknown

Eya4

2.7E-02

2.02

Involved ininterferon signalling

M x2

3.1E-02

2.02

Part of acute interferon inflammatory pathway

energy environment

Cell-m
atrix adhesion,

F n l associated

Downregulation causes decrease inmitochondrial
function, decrease cytosolic oxidative damage

Sodium-gated channel - linked to neurite
extension, cell adhesion, filipodia formation
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Ifnar2

3.7E-02

2.03

Interferon receptor component

Wdr62

1.1E-02

2.03

Involved instress granule translational repression

A ld h lll

2.1E-02

2.04

M
arker of astrocytes

Syk

1.3E-02

2.04

Obfc2a

2.9E-02

2.05

Single-stranded binding protein in D
N
Arepair

Ddb2

1.4E-02

2.05

UV-dam
age D
N
Arepair protein

Fine

4.6E-02

2.05

Links membrane proteins to actin cytoskeleton

4930452B06Rik

4.3E-02

2.05

Unknown

K n tcl

1.2E-02

2.05

Kinetochore-associated protein

A rh g e flO

1.7E-02

2.05

Cell-cycle (spindle assem
bly) control protein

Lamc2

3.0E-02

2.06

Lam
inin component

S ta b l

2.2E-02

2.06

Linked to dendrite formation and macrophage

Nos2 expression

A
G
E-induced phagocytosis and macrophage
adhesion
Roles in macrophage Nos2 expression, neurite

N o tch l

2.8E-03

2.06

BC006779

1.5E-02

2.07

Unknown

Klf4

4.0E-02

2.07

Regulates axon regeneration capability

M uc5b

4.3E-02

2.07

Upregulated in inflammation

Sfm bt2

3.2E-02

2.07

Developmental gene

Rgs22

4.5E-02

2.07

Regulator of G-protein signalling

Atp8b4

5.1E-03

2.08

A
TP-binding phospholipid transporter

Pde2a

1.6E-02

2.08

Calcium-dependent control of cA
M
P

C o l2 5 a l

2.8E-02

2.08

Basement membrane collagen

Tm b im l

3.9E-02

2.08

Apoptosis regulator - B
A
Xinhibitor

Abcc3

2.5E-03

2.08

A
TP-bindingglucuronated substrate transporter

Msn

4.9E-02

2.08

S u lt5 a l

1.8E-02

2.08

Sulfotransferase

B a ia p 2 ll

4.5E-02

2.08

A
ctin assembly and membrane protrusions

Pnpla7

4.1E-02

2.08

L
ipid metabolism(phospholipase)

Col5a2

3.4E-02

2.08

Collagen [corneal]

Tap2

1.3E-02

2.09

Neuroinflammatory antigen peptide transporter

Fgfr2

3.2E-02

2.09

C
ell survival/proliferation factor

Fb lim l

2.5E-02

2.10

Links cytoskeleton to cell junctions

Ecm 2

4.8E-02

2.10

Unknown

Dock2

2.1E-02

2.10

A
ctin regulation inm
icroglial chemotaxis

Ta f i d

8.6E-03

2.11

Required for transcription

Col l a 2

1.4E-02

2.12

Tissue repair collagen

formation, angiogenesis, and apoptosis

Cross-links actin to cell membrane, involved with
filipodia, axonal/neurite projections
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Skap2

2.6E-02

2.12

SR
Ckinase scaffold protein

M a g tl

2.3E-02

2.13

M
agnesiumtransporter - epithelium-specific

Neka p H

1.2E-02

2.13

Immune cell development and m
obility

C c d c l5 0

1.2E-02

2.13

Unknown

Cd68

2.0E-02

2.13

M
acrophage/microglia-specific cell antigen

Svepl

4.6E-02

2.14

Unknown

Frem2

2.3E-02

2.14

R
PEbasement membrane protein

Vw al

8.3E-03

2.14

Unknown

Pebp4

2.0E-02

2.14

Induces cell migration and survival

L rrk l

1.2E-02

2.15

Unknown

Gbp4

2.8E-02

2.15

Interferon-induced G
T
Phydrolysis

Plcl2

9.8E-03

2.15

Negative regulation of b-cell receptor

Ifih l

2.6E-02

2.15

Involved ininterferon expression

S g sm l

1.4E-02

2.16

C
N
SG-protein signalling regulator

Ccl24

2.1E-02

2.16

Eosinophil chemotactic factor

Kitl

3.1E-02

2.16

M
ast cell development

Kif20a

3.1E-02

2.16

K
inesin motor protein involved with cytokinesis

D n a h cl

9.0E-03

2.17

D
ynein heavy chain

Calcrl

2.0E-02

2.17

Calcitonin receptor

Abcc4

5.0E-02

2.18

A
TP-bindingorganic anion transport

A b c a l3

6.8E-03

2.18

Transporter with unknown function

H2-D1

2.3E-02

2.18

M
H
Ccom
plex 1protein

Hpse

3.6E-02

2.19

Degrades E
C
Mheparin, involved in inflammation

N t5 d cl

1.4E-03

2.20

5' Nucleotidase Protein

A b c a l2

2.1E-02

2.21

A
TP-binding lipidtransporter

Ecm l

1.3E-02

2.21

U
nknown

A b c a l6

4.3E-02

2.21

Transporter unknown function

P t h lr

4.1E-02

2.21

M ertk

1.6E-02

2.22

M yom 2

1.0E-02

2.22

Parathyroid hormone receptor-upregulated in
damaged neurites
Required for continual phagocytosis of
photoreceptor outer segments by R
P
Ecells
M
-band m
uscle component
Calcium
-activated chloride channel - upregulated

deal

3.8E-02

2.22

Pappa2

9.3E-03

2.23

Represses growth post-natally

AW 551984

2.0E-02

2.23

Unknown

Nrap

4.6E-02

2.23

Nebulin-related anchoring protein [m
uscle]

M yo5c

3.5E-03

2.24

Granule trafficking protein

Pld2

4.6E-02

2.24

Phospholipase D-lipid metabolism

inexcitotoxicity
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Serpina3a

4.6E-02

2.24

Serine peptidase inhibitor-Stress response

Iqgap3

1.5E-02

2.24

A
ctin organization inneurites

E rm p l

2.6E-02

2.24

Endoplasm
ic reticulummetallopeptidase

Tnxb

4.3E-02

2.24

Basement membrane-associated protein

Fut8

4.1E-02

2.25

A
dds fucose to glycopeptides

4933428G20Rik

3.5E-02

2.25

U
nknown

M pa2l

3.6E-02

2.25

M
acrophage activation marker

Trpm4

4.3E-02

2.25

M yof

6.0E-03

2.27

M
embrane fusion of vesicles

P k h d lll

8.4E-03

2.27

M
ay have role in im
m
unity

Poln

3.9E-02

2.28

Polymerase involved in D
N
Across-link repair

Fnl

1.6E-02

2.29

Sfrp4

1.7E-02

2.29

Wnt antagonist - anti-angiogenic

4930534B04Rik

1.0E-02

2.30

Unknown

M y h ll

2.7E-02

2.30

Smooth m
uscle m
yosin

P lin l

4.1E-02

2.31

M
ay inhibit lipolysis

Ccdc46

3.4E-02

2.31

Unknown

Efcab7

2.6E-03

2.33

Unknown

Scm l2

3.4E-02

2.33

Developmental gene

M y o l5 b

6.7E-03

2.34

Unknown

Cd93

3.8E-02

2.34

Present in inflammatory macrophages/microglia

M thfd2

3.9E-03

2.34

Purine metabolism

Aldh2

4.5E-02

2.34

Detoxification of metabolic aldehydes

Kynu

1.6E-02

2.35

Cleaves kynurenine, and has role in N
A
Dsynthesis

C920025E04Rik

3.7E-02

2.35

Calciumchannel active during A
T
Pdepletion of
microvasculature

E
C
Mprotein, upregulated inastrocyte activation
and aging

Unknown
Increases stability of FG
F23- preventing

Galnt3

2.9E-02

2.35

Dse

4.2E-02

2.37

Gpd2

4.0E-02

2.38

Upregulated in high glycolysis environment

Pdzrn4

2.5E-02

2.39

PD
Zdomain - unknown function

A d h fe l

3.6E-02

2.40

V ip rl

1.6E-02

2.41

Neuroprotective V
IPreceptor

Fxyd5

4.4E-02

2.41

Unknown

B2m

2.4E-02

2.42

M
H
Ccom
plex 1protein

Renbp

1.6E-02

2.42

Renin-binding protein

D ie d

2.8E-02

2.43

Tumour suppressor

m
ineralization
Chondroitin biosynthesis and glucuronic acid
metabolism

A
lcohol dehydrogenase - linkedto mitochondrial
stress
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Itpr2

3.9E-02

2.44

Induces intracellular C
a2
+release in response to IP3

Slc44a5

4.0E-02

2.44

Choline transporter

igtp

3.7E-02

2.44

Interferon-induced G
TPase- increases cell survival

Fas

1.6E-02

2.45

Mvp

2.3E-02

2.46

Transporter of unknown function

Ncapd2

2.7E-02

2.46

U
nknown

Sec16b

4.5E-02

2.47

Involved inendoplasmic reticulumtransport

T sp a n l2

4.6E-02

2.48

S lc l5 a l

4.9E-02

2.49

Oligopeptide transporter

O sm r

1.2E-02

2.49

Cytokine receptor involved ininflammation

Gm 7298

1.0E-02

2.49

U
nknown

Thsd7b

2.3E-02

2.52

U
nknown

17000I lF M R ik

1.6E-02

2.53

U
nknown

Clic5

4.5E-02

2.55

Chloride transporter

D ia p l

3.8E-02

2.55

Role inDrosophila axon elongataion

N u p l3 3

4.2E-02

2.55

Nuclear pore protein

M m e ll

1.9E-02

2.56

M
embrane endopeptidase

A tp lO d

4.9E-02

2.57

A
TP-coupled ion transport

Obfc2a

1.4E-02

2.58

Single-stranded D
N
Abinding protein - Repair

Nos2

3.2E-02

2.59

F3

3.8E-02

2.59

Coagulation factor

Dnahc8

3.1E-02

2.61

D
ynein heavy chain- ciliated cells

Sdk2

4.2E-02

2.61

Synaptic scaffold protein

P o la l

8.2E-03

2.61

Replication-initiating D
N
Apolymerase

M y o le

2.5E-03

2.62

Intracellular m
yosin

D ysf

1.3E-02

2.64

Related to m
uscle

Zfp748

4.9E-02

2.68

Zinc-finger protein, unknown function

Csm d2

5.0E-03

2.69

Unknown

MHt4

4.5E-02

2.70

Involved insynaptic remodellingand cell adhesion

Cast

1.9E-03

2.71

Inhibitor of calpain

A o x 3 ll

1.5E-02

2.71

O
xidizes aldehydes to acids

Asah2

1.3E-02

2.72

Sphingolipid metabolism

Fn d c3 cl

7.5E-03

2.73

U
nknown

Lam a3

3.2E-03

2.79

Lam
inin component

Rassf2

4.9E-02

2.79

Ras-associated pro-apoptotic protein

M ugl

1.5E-02

2.80

U
nknown

Receptor for Natural K
illerT-cell-mediated
apoptosis

Activates m
atrix metalloproteases in retinal
vasculature

Creates N
Oduring inflammation, linkedto
neurotoxicity
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C p sl

2.4E-02

2.81

Detoxifies ammonia fromprotein catabolism

I ll 8 r l

3.9E-02

2.81

Cytokine receptor related to innate im
m
unity

M yh9

2.6E-02

2.82

Leukocyte-specific m
yosin

B230120H23Rik

3.5E-02

2.83

Unknown

Utp20

2.9E-02

2.84

Ribosom
e assembly intermediate

A b c a lS

1.3E-02

2.85

A
TP-bindingtransporter - unknown function

A d cylO

5.1E-03

2.86

Creates cA
M
P

D ocklO

9.0E-03

2.90

Unknown

Hhip

8.7E-03

2.92

Nrk

1.4E-02

2.94

Clspn

3.5E-03

2.94

Gm nn

2.2E-02

2.99

Involved inS/Mphase transition

Cd97

1.5E-02

3.00

Leukocyte marker

Xdh

6.5E-03

3.00

Involved in purine metabolismand R
O
Sgeneration

M y o le

3.7E-02

3.01

Intracellular m
yosin in membrane rem
odelling

C d k n la

4.7E-02

3.03

Inhibitor of the cell cycle (p21)

A ls2cl

2.8E-02

3.04

Endosomal protein

M y o lf

1.7E-04

3.04

Intracellular m
yosin

H2-K1

3.7E-02

3.07

M
H
C1component

Nfkbil2

2.1E-02

3.15

Inhibitor of N
F
-K
B

F13al

2.3E-02

3.21

Coagulation factor

P le d

2.5E-02

3.23

Kif4

7.3E-03

3.37

Sequesters Sonic

hedgehog protein (development)

Required for JN
Kactivation
G
2/S phase checkpoint, upregulated with D
N
A
damage

Unknown
K
inesin motor protein necessaryfor neuron
survival/axon transport
Upregulated via glucose-induced R
O
S, associated

Trpm 6

4.4E-02

3.48

Csm d3

2.1E-02

3.53

Unknown

B u b lb

5.0E-03

3.78

Spindle assembly checkpoint

Dpp4

1.8E-02

4.03

Cleaves neuropeptide Y
, involved ininflammation

M uc5ac

1.8E-02

4.03

Upregulated in inflam
m
ation

Dock11

5.4E-03

4.18

Lym
phocyte specific protein

with calciuminfluxand monocyte activation

Selection criteria for differentially-expressed genes were a minimum fold change of 2
and a p-value less than 0.05. Gene order was determined according to fold-change value.
* Annotation was based on Pubmed [National Institute of Health. Bethesda, MD]
literature surveys using the gene name in combination with other keywords such as
“mitochondria”, “retina”, “neuron” and “inflammation”
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Table C.2. List of genes differentially expressed in 4-month-old hq disease mouse
cerebellum.+i
Fold

Function

Gene Sym
bol

p-Value

Car4

8.7E-04

-2.64

Carbonic Anhydrase

Tnc

1.0E-04

-2.62

Tenasin C
, Involved in neuronal plasticity, E
C
M

Bclp2

1.3E-03

-2.21

Unknown

Eom es

3.0E-03

-2.08

Cd53

7.1E-04

2.00

Leukocyte Surface antigen

Cd34

1.5E-04

2.01

Blocker of adhesion, increases mast cells m
obility

B2m

4.6E-03

2.01

M
H
C1component

F o x fla

1.3E-02

2.02

Developmental gene

Slc43a3

7.2E-04

2.02

Angiogenesis-linked, norm
ally embryonic

Fnl

1.9E-03

2.05

Emcn

2.6E-03

2.05

Ctss

1.9E-04

2.06

M
icroglial lysosom
al protease

Hexb

1.2E-03

2.10

lysosom
al enzyme found in m
icroglial cells

Change

Required in hippocampal neurogenesis and
immune

E
C
Mprotein, upregulated inastrocyte activation
and aging
Anti-adhesive activity (em
bryonic)

Cd68

1.9E-03

2.10

M
acrophage/microglial cell surface antigen

Cd24a

2.2E-02

2.12

Linked to neurite outgrowth, cell adhesion

Bcl6b

5.3E-04

2.12

Involved inT-cell function

C y b 5 rl

1.9E-04

2.15

Cytochrome b5 reductase

Prokr2

1.7E-03

2.16

Eng

1.4E-03

2.24

Ly6a

1.0E-02

2.26

Protein receptor related to circadian energy
consumption/locomotor activity
Angiogenesis protein
Lym
phocyte antigen, causes upregulation of
m
atrix metalloproteases
Interferon induced protein - involved in

Ifitm3

6.8E-04

2.33

A g x t2 ll

4.3E-03

2.35

Unknown function, associated with Schizophrenia

Acta2

3.6E-03

2.38

Smooth m
uscle actin

Tm e m l76a

7.6E-04

2.41

Unknown

Cdh23

1.5E-04

2.43

H
air cell bundle cell adhesion - also in retina

Lyz2

5.8E-03

2.46

Lysosom
al protease related to macrophages

Laptm 5

7.9E-04

2.48

Cyr61

inflammation

Lysosom
al membrane associated protein
Cysteine-rich angiogenic factor - roles in E
C
M

1.9E-02

2.69

organization, wound repair, apoptosis
Cathepsin Cinhibitor, m
aydirect im
m
une

Cst7

8.0E-03

2.70

E ltd l

1.7E-05

2.83

Found in microvascular endothelium

Slc7a3

2.1E-04

3.19

Transports A
rginine required for neuron growth

Txnip

1.3E-03

3.22

M
ediates inflammosome via N
R
L
P3, R
O
S

function

137
dependent action - increases apoptosis

Cd93
Ednl

1.7E-04
4.5E-03

3.28
3.32

Rem
oval of apoptotic cells
Promotes cell migration via M
M
P9 (worsening
inflammation)

C4b

1.0E-05

3.93

Complement immune pathway

Ly86

2.9E-04

4.11

Lym
phocyte antigen - innate im
m
unity

Serpina3n

1.6E-04

4.52

Stress response gene - neural damage

Gfop

8.3E-06

5.28

Astrocyte activation marker

M ela

9.6E-05

11.78

M
elanoma Antigen

Selection criteria for differentially-expressed genes were a minimum fold change o f 2
and a p-value less than 0.05. Gene order was determined according to fold-change value.
1 Annotation was based on Pubmed [National Institute of Health, Bethesda, MD]
literature surveys using the gene name in combination with other keywords such as
“mitochondria”, “retina”, “neuron” and “inflammation”.
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Table

C.3. List of genes differentially expressed in the 4-month-old hq disease mouse

cerebellum used for KEGG pathway analysis.T

Gene Sym
bol

p-Value

Fold Change

Car4

8.7E-04

-2.64

Tnc

1.0E-04

-2.62

Bclp2

1.3E-03

-2.21

Eom es

3.0E-03

-2.08

Plk5

1.6E-03

-1.98

D17H6S56E-3

9.6E-04

-1.89

0 lfr l2 7 0

1.9E-02

-1.89

Stap2

1.3E-03

-1.86

Syne2

6.0E-04

-1.86

C a cn a le

1.2E-04

-1.77

Fstl5

2.0E-04

-1.72

S id tl

1.8E-05

-1.63

Otx2

2.4E-02

-1.62

O lfrl2 4

4.5E-02

-1.61

Tbata

4.4E-04

-1.60

Svepl

3.5E-02

-1.60

C a c n a lc

8.9E-06

-1.58

D0H4S114

8.2E-03

-1.56

Fxyd6

2.1E-03

-1.56

Pappa

4.6E-02

-1.55

Abca8b

2.8E-03

-1.55

Ryr3

3.5E-03

-1.54

Slc24a5

2.2E-02

-1.54

P ro x l

8.9E-04

-1.53

0lfr304

1.2E-02

-1.53

Gap43

1.3E-03

-1.51

Nhlh2

1.0E-02

-1.50

R n fl4 8

1.3E-02

-1.50

Bhlhe41

9.3E-03

1.50

Csm d3

2.2E-02

1.50

Ill3 r a l

1.1E-03

1.50

Rhoj

2.8E-03

1.50

Fyb

4.8E-03

1.50

Ig sflO

4.1E-02

1.51

G m 10561

1.2E-02

1.51

1810011010Rik

7.6E-03

1.51

S lc 2 6 a l0

2.8E-03

1.51
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2 8 1 0 4 5 9 M llR ik

5.4E-03

1.51

Atf3

3.7E-04

1.51

Lgals3bp

1.9E-02

1.51

C lq a

3.7E-04

1.51

E m rl

4.2E-03

1.51

Asns

1.2E-03

1.51

Rad54l

8.5E-03

1.52

Esam

3.1E-03

1.52

3200002M 19Rik

3.6E-03

1.52

Casp8

1.9E-03

1.52

Cd97

1.4E-02

1.52

S lc l4 a l

2.3E-02

1.52

Ddx58

8.5E-04

1.52

Nes

6.0E-03

1.52

C xcllO

2.3E-02

1.52

Itpkb

2.4E-03

1.52

Yars

8.2E-03

1.52

Ptges

3.4E-04

1.52

P h yh d l

2.2E-02

1.53

Kdr

2.6E-03

1.53

Irg m l

7.8E-04

1.53

Tm e m l76b

1.5E-04

1.53

T in a g ll

3.9E-03

1.53

Ptprb

1.9E-02

1.53

Havcr2

4.0E-02

1.53

H 2 -g sl0

7.7E-03

1.54

T a s2 rl3 5

5.9E-03

1.54

Coleri

1.4E-02

1.54

Egfl7

7.9E-03

1.54

C a s p l2

5.9E-03

1.54

Klf4

1.8E-02

1.54

P p a p d cla

6.0E-04

1.55

Oasl2

9.2E-03

1.55

Pdgfb

5.0E-04

1.55

S o x l7

2.2E-03

1.55

L e c tl

1.1E-02

1.55

Itgam

4.3E-03

1.55

P v tl

6.7E-03

1.55

P lxn d l

4.4E-03

1.56

Agt

2.1E-02

1.56

Gjb6

3.0E-02

1.56

T m 4sfl

7.6E-04

1.56

Rhoc

2.0E-03

1.56
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Xpot

5.1E-03

1.57

Car5b

6.9E-03

1.57

Cdh5

1.5E-03

1.57

C y y rl

2.0E-02

1.57

C cn d l

4.4E-04

1.57

Lum

2.1E-02

1.57

C4a

2.0E-02

1.57

S fp il
Lrrc32

2.4E-02

1.57

1.1E-03

1.57

Cfh

2.4E-04

1.57

Chad

5.7E-03

1.57

U s p l8

2.3E-03

1.57

Il2rg

1.8E-03

1.58

Maob

8.1E-03

1.58

Th

3.4E-02

1.58

Ifitm 2

6.0E-04

1.58

Opn3

2.3E-02

1.58

Eif2ak2

8.7E-03

1.58

A830018L16Rik

1.9E-04

1.58

G m l2 9

6.3E-03

1.59

Cd33

2.0E-03

1.59

Cp

3.4E-03

1.59

H2-Q 7

2.9E-02

1.59

Paqr3

2.6E-02

1.59

Fbln5

3.3E-03

1.59

M pegl

5.5E-03

1.59

Ly6c2

6.6E-03

1.60

C 3 a rl

1.2E-02

1.60

Lgals9

1.2E-03

1.61

P ro s l

5.6E-03

1.61

Igfbp7

5.7E-04

1.61

Cd38

1.7E-02

1.61

Neka p H

1.2E-03

1.61

C h i3 ll

1.9E-04

1.61

Reep6

5.3E-03

1.61

Shm t2

3.6E-03

1.62

Stard5

3.9E-03

1.62

H rsp l2

1.1E-02

1.62

Fxyd5

9.6E-03

1.62

T a fld

4.8E-03

1.63

A ld h ll2

3.0E-03

1.63

Plscr2

3.6E-03

1.63

Csf3r

3.8E-03

1.64
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C3

4.5E-04

1.64

Pld4

2.3E-02

1.65

T im p l

3.0E-03

1.65

Cnn2

6.5E-04

1.65

E n tp d l

1.2E-02

1.66

F o x fla

2.8E-03

1.68

P y crl

1.8E-03

1.69

Cd 180

5.4E-03

1.70

Itg a l

8.1E-03

1.70

G p r ll6

7.2E-03

1.70

F3

2.2E-03

1.71

Krt25

1.6E-02

1.71

Ly 6 c l

9.8E-03

1.72

Sesn2

3.2E-03

1.74

Ddit3

5.0E-03

1.75

Sem a3d

3.8E-03

1.76

Ctsh

1.5E-05

1.77

Podxl

1.2E-03

1.77

C x c ll3

1.4E-02

1.77

Sem a3c

5.5E-03

1.77

Ddr2

5.1E-03

1.78

C s flr

2.1E-03

1.78

Mgp

5.7E-03

1.80

H2-K1

1.2E-02

1.81

Fee r ig

3.3E-04

1.81

M thfd2

4.2E-04

1.81

If it3

1.0E-03

1.82

S lc la 4

2.4E-03

1.82

Slc7a5

2.1E-04

1.83

C x c ll2

4.3E-04

1.83

Anxa3

1.2E-02

1.85

P e ca m l

2.3E-03

1.85

Ccl3

3.9E-04

1.86

Osm r

4.9E-03

1.88

Itm 2a

1.2E-03

1.89

Gpx3

1.4E-02

1.92

Cavi

1.8E-03

1.94

Ifitl

1.2E-03

1.96

Ifi203

2.5E-02

1.96

C lq b

3.1E-03

1.97

Tyrobp

4.0E-03

1.97

C lq c

1.0E-03

1.98

Cd53

7.1E-04

2.00

142
Cd34

1.5E-04

2.01

B2m

4.6E-03

2.01

Slc43a3

7.2E-04

2.02

Fnl

1.9E-03

2.05

Emcn

2.6E-03

2.05

Ctss

1.9E-04

2.06

Hexb

1.2E-03

2.10

Cd68

1.9E-03

2.10

Cd24a

2.2E-02

2.12

Bcl6b

5.3E-04

2.12

C yb 5 rl

1.9E-04

2.15

Prokr2

1.7E-03

2.16

Eng

1.4E-03

2.24

Ly6a

1.0E-02

2.26

Ifitm3

6.8E-04

2.33

A g x t2 ll

4.3E-03

2.35

Acta2

3.6E-03

2.38

T m e m l7 6 a

7.6E-04

2.41

Cdh23

1.5E-04

2.43

Lyz2

5.8E-03

2.46

Laptm5

7.9E-04

2.48

Cyr61

1.9E-02

2.69

Cst7

8.0E-03

2.70

E ltd l

1.7E-05

2.83

Slc7a3

2.1E-04

3.19

Txnip

1.3E-03

3.22

Cd93

1.7E-04

3.28

Ednl

4.5E-03

3.32

C4b

1.0E-05

3.93

Ly86

2.9E-04

4.11

Serpina3n

1.6E-04

4.52

Gfap

8.3E-06

5.28

Mela

9.6E-05

11.78

Selection criteria for differentially-expressed genes were a minimum fold change of 1.5
and a p-value less than 0.05. Gene order was determined according to fold-change value.

